2018N361438_05 CONFIDENTIA L
GlaxoSmithKline group of companies 209275
1TITLE PA GE
Protocol Title: A Three -Part FTIH Stud y to Evaluate Safet y, Tolerability, 
Pharmacokinetics and Pharmacod ynamics of Single and Repeat Oral Doses of 
[COMPANY_004]3439171A, in a Randomized, Double -Blind (sponsor unblinded), Placebo -
Controlled, Dose Escalatio n study  and to Evaluate the Effect of Food on a Single Oral 
Dose of [COMPANY_004]3439171A in Health y Adult Participants
Protocol Number: 209275 /Amendment 03
Compound Number: [COMPANY_004]3439171
Study Phase: Phase 1
Short Title: FTIH Study to evaluate the safet y, pharmacok inetics, and 
pharmacod ynamics of single and repeat doses of [COMPANY_004]3439171A in healthy participants; 
food effect
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_274034] Information can be found in the Study  Reference 
Manual
Regulatory Agency Identifying Number(s): 
IND: 139312
Approval Date: 09-MAY-2019
Copy right 2019the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthori sed cop ying or use of this information is prohibited.
2018N361438_05  CONFIDENTIAL   209275  
 

SPONSOR SIGNATORY: 
 
 
 
 
 
      05/09/2019 

David Neil, MD MFPM       Date 
Clinical Director, MM-DPU, FPD 










  2 
[COMPANY_003]
[COMPANY_003]
2018N361438_05 CONFIDENTIA L
[ADDRESS_274035] dates of original protocol and all amendments in reverse chronological order.
Document Date DNG Number
Amendment 3 09-MAY -2019 2018N361438_05
Amendment 2 13-MAR -2019 2018N361438_04
Republishing -Amendment 1 31-AUG -2018 2018N361438_03
Republished -Amendment 1 29-AUG -2018 2018N361438_02
Amendment 1 27-AUG -2018 2018N361438_01
Original Protocol 3-JUL-2018 2018N361438_00
Amendment 3:09-MAY -2019
Overall Rationale for the Amendment: Part B has been updated with an additional 
subpart to examine repeat doses of [COMPANY_004]3439171 for a shorter duration at hig her 
exposures .This will help characterize the PK and safet y at higher exposures 
corresponding to the predicted therapeutic dose. The I C50 of [COMPANY_004]3439171 has also been 
updated to correct the minute typographic error in the ng/mL value as per the human 
HPGDS enzyme assay .Minor editorial changes have also been made in the protocol.
Section # and Name [CONTACT_23688]
1.[ADDRESS_274036] changes in 
exposure limits7 Day repeat dosing will be 
performed in Part B to characterize 
PK and safety of [COMPANY_004]3439171 at 
higher exposures for a shorter 
duration
3 Objectives and 
EndpointsAddition of Ctrough samples 
during 7 day dosing period7 Day repeat dosing will be 
performed in Part B to characterize 
PK and safety of [COMPANY_004]3439171 at 
higher exposures for a shorter 
duration
2018N361438_05 CONFIDENTIA L
209275
4Section # and Name [CONTACT_23688]
4.[ADDRESS_274037] changes in 
increased exposure limits7 Day repeat dosing will be 
performed in Part B to characterize 
PK and safety of [COMPANY_004]3439171 at 
higher exposures for a shorter 
duration
4.3 Dose Justification Update for consistency of 
units (ng/mL) based on the 
human HPGDS enzyme 
assay[COMPANY_004]3439171 concentrations will b e 
reported in units (ng/mL) and based 
on the corrected human HPGDS 
enzyme assay, IC50 is 7.77 ng/mL 
which was previously written in a 
minor error.
6.[ADDRESS_274038] 
increased exposure limits for 
7 day dosing7 Day repeat dosing will be 
performe d in Part B to characterize 
PK and safety of [COMPANY_004]3439171 at 
higher exposures for a shorter 
duration.
9.4 Statistical Analysis Addition of days due to 7 day 
dosing cohort in Part B7 Day repeat dosing will be 
performed in Part B to characterize 
PK and safet y of [COMPANY_004]3439171 at 
higher exposures for a shorter 
duration.
Throughout Updated language to align to 
addition of 7 day dosing in 
Part B7 Day repeat dosing will be 
performed in Part B to characterize 
PK and safety of [COMPANY_004]3439171 at 
higher exposures for a sh orter 
duration.
2018N361438_05 CONFIDENTIA L
209275
5TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE................................ .....3
1.PROTOCOL SUMMARY ................................ ................................ .......................... 8
1.1. Synopsis ................................ ................................ ................................ .......8
1.2. Schema ................................ ................................ ................................ ......12
1.3. Schedule of Activities (SoA) ................................ ................................ ........ 14
2.INTRODUCTION ................................ ................................ ................................ ....48
2.1. Study Rationale ................................ ................................ .......................... 48
2.2. Backgro und................................ ................................ ................................ 48
2.2.1. Hematopoietic prostaglandin D2 synthase (H -PGDS) .................. 48
2.2.2. [COMPANY_004]3439171A ................................ ................................ ............. 49
2.3. Benefit/Risk Assessment ................................ ................................ ............ 49
2.3.1. Risk Assessment: ................................ ................................ ........ 51
2.3.2. Benefit Assessment ................................ ................................ .....55
2.3.3. Overall Benefit: Risk Conclusion ................................ .................. 55
3.OBJECTIVES AND ENDPO INTS ................................ ................................ ........... 55
4.STUDY DESIGN ................................ ................................ ................................ ....57
4.1. Overall Design ................................ ................................ ............................ 57
4.2. Scientific Rationale for Study Design ................................ .......................... 59
4.3. Justification for Dose ................................ ................................ .................. 60
4.3.1. Maximum Recommended Starting Dose (MRSD) ........................ [ADDRESS_274039] Level (MABEL) 
Dose ................................ ................................ ............................ 63
4.3.4. Dose Predicted to Achieve Exposure at the NOAEL Dose 
Level and Single Dose Stoppi[INVESTIGATOR_227499] ................................ .......... 63
4.3.5. Summary ................................ ................................ ..................... 63
4.4. End of Study Definition ................................ ................................ ............... 63
5.STUDY POPULATION ................................ ................................ ........................... 64
5.1. Inclusion Crite ria................................ ................................ ......................... 64
5.2. Exclusion Criteria ................................ ................................ ........................ 65
5.3. Lifestyle Considerations ................................ ................................ .............. 67
5.3.1. Meals and Dietary Restrictions ................................ .................... 67
5.3.2. Caffeine, Alcohol, and Tobacc o................................ ................... 68
5.3.3. Activity ................................ ................................ ......................... 68
5.4. Screen Failures ................................ ................................ ........................... 68
6.STUDY INTERVENTION ................................ ................................ ........................ 69
6.1. Study Intervention(s) Administered ................................ ............................. 69
6.2. Preparation/Handling/Storage/Accountability ................................ .............. 70
6.3. Measures to Minimize Bias: Randomization and Blinding ........................... 71
6.3.1. Randomization ................................ ................................ ............. 71
6.3.2. Blinding ................................ ................................ ........................ 72
6.4. Study Intervention Compliance ................................ ................................ ...73
2018N361438_05 CONFIDENTIA L
209275
66.5. Concomitant Therapy ................................ ................................ .................. 74
6.6. Dose Modification ................................ ................................ ....................... 74
6.6.1. Dose Escalation in Part A ................................ ............................ 75
6.6.2. Dose escalation in Part B ................................ ............................. 76
6.7. Intervention after the End of the Study ................................ ........................ 77
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/W ITHDRAW AL................................ ................................ .....77
7.1. Discontinuation of Study Intervention ................................ .......................... 77
7.1.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................ ................ 77
[IP_ADDRESS]. Study Intervention Restart or Rechallenge after 
liver stoppi[INVESTIGATOR_31735] ................................ ............ 78
7.1.2. QTc Stoppi[INVESTIGATOR_2121] ................................ ................................ ..78
7.1.3. Individual Stoppi[INVESTIGATOR_2121] ................................ .......................... 79
7.1.4. Dose Adjustment/Discontinuation Pharmacokinetic Criteria ......... 79
7.1.5. Temporary Discontinuation ................................ .......................... 79
7.1.6. Study Stoppi[INVESTIGATOR_2121] ................................ ................................ 79
[IP_ADDRESS]. Safety Study Stoppi[INVESTIGATOR_2121] ................................ ....79
[IP_ADDRESS]. PK Study Stoppi[INVESTIGATOR_2121] ................................ ......... 80
7.2. Participant Discont inuation/W ithdrawal from the Study ............................... [ADDRESS_274040] to Follow Up ................................ ................................ ........................ 80
8.STUDY ASSESSMENTS AN D PROCEDURES ................................ ..................... 81
8.1. Efficacy Assessments ................................ ................................ ................. 81
8.2. Safety Assessments ................................ ................................ ................... 82
8.2.1. Physical Examinations ................................ ................................ .82
8.2.2. Vital Signs ................................ ................................ .................... 82
8.2.3. Electrocardiograms ................................ ................................ ......82
8.2.4. Telemetry ................................ ................................ ..................... 83
8.2.5. Holter Monitoring ................................ ................................ ......... 83
8.2.6. Clinical Safety Laboratory Assessments ................................ ......84
8.2.7. Hormone Monitoring ................................ ................................ ....84
8.2.8. Suicidal Ideation and Behaviour Risk Monitoring ......................... 85
8.3. Adverse Events and Serious Adverse Events ................................ ............. 85
8.3.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................ ................................ ................... 85
8.3.2. Method of Detecting AEs and SAEs ................................ ............. 85
8.3.3. Follow -up of AEs and SAEs ................................ ......................... 86
8.3.4. Regulatory Reporting Requirements for SAEs ............................. 86
8.3.5. Pregnancy ................................ ................................ ................... 86
8.4. Treatment of Overdose ................................ ................................ ............... 86
8.5. Pharmacokinetics ................................ ................................ ....................... 87
8.5.1. Blood Sample Collection ................................ .............................. 87
8.5.2. Urine Sample Collection ................................ .............................. 87
8.5.3. Bile Sample Collection ................................ ................................ .88
8.5.4. Sample Analysis ................................ ................................ .......... 88
8.6. Pharmacodynamics ................................ ................................ .................... 88
8.6.1. Urine Pharmacodynamics Assessment ................................ ........ 89
8.6.2. Muscle Biopsy ................................ ................................ ............. 89
8.7. Genetics ................................ ................................ ................................ .....89
8.8. Biomarkers ................................ ................................ ................................ .89
2018N361438_05 CONFIDENTIA L
209275
78.9. Health Economics or Medical Resource Utilization and Health 
Economics ................................ ................................ ................................ ..89
9.STATISTICAL CONSIDER ATIONS ................................ ................................ ........ 90
9.1. Statistical Hypotheses ................................ ................................ ................. 90
9.2. Sample Size Determination ................................ ................................ ........ 90
9.3. Populations for Analyses ................................ ................................ ............ 90
9.4. Statistical Analyses ................................ ................................ ..................... 91
9.4.1. Safety Analyses ................................ ................................ ........... 94
9.4.2. Other Analyses ................................ ................................ ............ 94
9.5. Interim Analyses ................................ ................................ ......................... 94
9.5.1. Data Monitoring Committee (DMC) ................................ .............. 94
10.SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ................................ ................................ ............................... 95
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ................................ ................................ ............................ 95
10.1.1. Regulatory and Ethical Considerations ................................ ........ 95
10.1.2. Financial Disclosure ................................ ................................ .....95
10.1.3. Informed Consent Process ................................ .......................... 96
10.1.4. Data Protection ................................ ................................ ............ 96
10.1.5. Dissemination of Clinical Study Data ................................ ........... 97
10.1.6. Data Quality Assurance ................................ ............................... 97
10.1.7. Source Documents ................................ ................................ ......98
10.1.8. Study and Site Closure ................................ ................................ 99
10.1.9. Publication Policy ................................ ................................ ......... 99
10.2. Appendix 2: Clinical Laboratory Tests ................................ ....................... 100
10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ................................ .....102
10.3.1. Definition of AE ................................ ................................ .......... 102
10.3.2. Definition of SAE ................................ ................................ ........ 103
10.3.3. Recording and Follow -Up of AE and SAE ................................ ..104
10.3.4. Reporting of SAE to [COMPANY_004] ................................ ........................... 106
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................ ................................ ................................ 107
10.4.1. Contraception Guidance: ................................ ........................... 107
10.4.2. Collection of Pregnancy Information: ................................ ......... 108
10.5. Appendix 5: Genetics ................................ ................................ ................ 109
10.6. Appendix 6: Liver Safety: Required Actions a nd Follow -up 
Assessments ................................ ................................ ............................ 110
10.7. Appendix 7: Abbreviations and Trademarks ................................ .............. 112
10.8. Appendix 8: Protocol Amendment History ................................ ................. 116
11.REFERENCES ................................ ................................ ................................ .....119
2018N361438_05 CONFIDENTIA L
209275
81. PROTOCOL SUMMA RY
1.1. Synopsis
Protocol Title : A Three -Part FTIH Stud y to Evaluate Safet y, Tolerability, 
Pharmacokinetics and Pharmacod ynamics of Singl e and Repeat Oral Doses of 
[COMPANY_004]3439171 A, in a Randomized, Double -Blind (sponsor unblinded), Placebo -
Contr olled, Dose Escalation study  and to Evaluate the Effect of Food on a Single Oral 
Dose of [COMPANY_004]3439171 A in Healthy  Adult Participants
Short Title: FTIH Study to evaluate the safet y, pharmacokinetics, and 
pharmacod ynamics of single and repeat doses of [COMPANY_004]34391 71A in healthy participants; 
food effect
Rationale: The FTIH study  with [COMPANY_004]3439171A will evaluate the safet y of 
[COMPANY_004] 3439171 A in healthy participants in order to avoid confounding factors due to the 
disease or concomitant drugs in patients. The study  design is based on pre -clinical 
findings for [COMPANY_004] 3439171 A, contributing to the frequency , type and duration of safet y 
assessment and monitoring during treatment periods in each cohort.
The single dose assessments in Part A will be conducted to determine safet y, tolerability , 
pharmacokinetics ( PK), and pharmacod ynamics ( PD)of the stud y intervention in 
individuals before progressing to doses explored further in other parts of the study  and 
will allow for an y adjustments needed based on emerging safet y, tolerability ,and PK 
information. Part A will also serve to identify  a dose for use in examining the effect of 
food on [COMPANY_004]3439171A exposure in Part C.
In Part B, a single dose safet y, tolerability  and PK will be collected followed by
[CONTACT_227535] t o the repeat dose portion of the study . The up to 14 -day 
dosing was chosen as it is thought to provide sufficient safet y and tolerability  data to 
bridge to longer duration studies. The dosing period can be adjusted depending on PK 
and PD data collected in Part A of the stud y. Part B will involve more detailed 
PK/PD/metabolite assessments to better understand the impact of [COMPANY_004]3439171A on 
target engagement and metabolism in humans. In addition, based on the PK obtained in 
Part A, an additional cohort will be enrolled to study  higher exposures of [COMPANY_004]3439171A 
for a shorter duration of time.
2018N361438_05 CONFIDENTIA L
209275
9Objectives and Endpoints :
Objective Endpoint
Primary
 To assess the safet y and 
tolerability  of [COMPANY_004]3439171A 
following single and repeat doses 
in healthy  participants
To chara cterize the PK of 
[COMPANY_004]3439171A, following single 
and repeat doses in healthy  
participantsAdverse events (AE), clinical 
laboratory  values, vital signs, 
and electrocardiograms (ECG)
Derived PK parameters for 
[COMPANY_004]3439171A including area 
under the plasma dru g 
concentration versus time curve 
(AUC(0 -t), AUC(0 -inf), 
maximum observed plasma drug 
concentration (Cmax), time to 
maximum observed plasma drug 
concentration (t max), and 
apparent terminal half -life (t 1/2) 
as appropriate
Secondary
To assess the effect o f food on the 
PK of [COMPANY_004]3439171A following an 
oral dose in health y participants 
To assess preliminary  dose 
proportionality  of [COMPANY_004]3439171A 
following single and re peat oral 
doses, as data permitDerived PK parameters for 
[COMPANY_004]3439171A including area under 
the plasma drug concentration vers us 
time curve (AUC(0 -t), AUC(0 -inf), 
maximum observed plasma drug 
concentration (Cma x), time to 
maximum observed plasma drug 
concentration (tmax), and apparent 
terminal half -life (t 1/2) as appropriate
AUC(0 -t), AUC(0 -inf), and Cmax 
following single dose and AUC(0 -τ) 
and Cmax following repeat dose for 
the assessment of dose 
proportionality
2018N361438_05 CONFIDENTIA L
209275
10Objective Endpoint
To examine the extent of 
accumulation and achievement of 
steady -state following repeat oral 
doses of [COMPANY_004]3439171A, as data 
permitsDetermine observed accumulation 
based on AUC(Ro) and Cmax
(RCmax) and determine the stead y-
state ratio (Rss) 
Trough plasma concentrati ons at the 
end of the dosing interval (C τ) 
collected pre -dose for repeat doses 3, 
4, 12, 13,and 14 (or repeat doses 
3,4,6, and 7 during 7 day  repeat 
dosing period) to assess the 
achievement of stead y-state of 
[COMPANY_004]3439171A .
Exploratory
 To evaluate the PD properties of 
[COMPANY_004]3439171A
To assess the effect of 
[COMPANY_004] 3439171 Aon QTc in healthy  
adult volunteers
To evaluate additional 
biomarkers of [COMPANY_004]3439171A 
target engagement after single 
and repeat doses.
To investigate the plasma, 
urinary  and biliary  (Par t B) 
metabolic pathway s of 
[COMPANY_004]3439171A in healthy 
subjects .Levels of mediators on 
prostaglandin and/or 
inflammatory  metabolic pathway s 
such as, but not limited to, PGD2, 
and PGE2. 
Holter monitor data collection 
and storage for evaluation of the 
correlati on between plasma levels 
of [COMPANY_004] 3439171 Aand changes in 
the QTc interval in the future, if 
appropriate
Levels of change in novel 
biomarkers in blood, muscle, or 
urine, such as, but not limited to, 
urine tetranor PGDM and PGEM 
(tPGDM, tPGEM), PGD2, and 
PGE2
[COMPANY_004]3439171 A-related material 
in plasma, urine and bile
2018N361438_05 CONFIDENTIA L
209275
11Overall Design:
Part A is a randomized, double blind (sponsor unblinded), placebo -controlled, crossover , 
single dose escalation study  in healthy  participants. Participants will be randomized to 
placebo or active stud y intervention groups after screening.
Part B is a randomized, double blind (sponsor unblinded), placebo -controlled, parallel 
group, repeat dose escalation study  in healthy  participants. Participants will be 
randomized to placebo or a ctive study  intervention groups after screening.
Part C is a randomized, open label, crossover, food effect study  in healthy  participants. 
Participants will be randomized to fed or fasted groups after screening.
Disclosure Statement: 
Part A is aCrossover group single ascending dose study  with 2 arms per cohort that is 
participant and investigator blinded.
Part B is a Parallel group repeat dose study  with 2 arms per cohort that is participant and 
investigator blinded.
Part C is a Crossover group food effec tstudy  with 2 arms per cohort that is not -masked.
Number of Participants:
Approximately  150participants will be screened to achieve 75randoml y assigned to 
study  intervention and 75 evaluable participants for an estimated total of 27evaluable 
participan tsin Part A, 36 evaluable participants in Part B, and 12 evaluable participants 
in Part C. Additional participants/cohorts may  be enrolled to allow for evaluation of 
additional dose levels .
Intervention Groups and Duration:
Part A will be a double -blind (sponsor unblinded), single oral dose, dose -rising, placebo -
controlled, randomized (with respect to placebo allocation), 3 period crossover study  in 
approximately  3 cohorts of participants.  Participants will be enrolled in the study  for 
approximately  10 weeks (a pproximately  30 day s screening, 3 in-house dose assessment 
periods of approximately 6days,3 wash out periods between each dose of approximately  
7 day sand an approximately  14 day  follow -up period) .
Part B will be double -blind (sponsor unblinded), up to 14 day  repeat oral dosing, placebo -
controlled, randomized (with respect to placebo allocation), dose escalation study  with at 
least three (single or twice -daily) repeat dose levels in 3 separate cohorts of participants 
who were not enrolled into Part s A or C of this study . Participants will be enrolled in the 
study for approximately  9 weeks ( approximately  30 d ays screening, approximately 15-22
day in-house dose assessment period, and an approximately  14 day  follow -up period. 
Part C will be an unblind ed, randomized, crossover study  where a single dose will be 
administered fasted or fed conducted in a separate cohort of participants than those who 
2018N361438_05 CONFIDENTIA L
209275
12were enrolled in Parts A or B. Participants recruited into Part C will spend approximately  
8 weeks enrolled in the study  (approximately  30 day s screening, approximately  5 day  in-
house assessment period, and an approximately  14 day  follow -up period.
Data Monitoring Committee: Dose Escalation Committee
1.2. Schema
Part A: Single Ascending Dose 
Figure 1 Single A scending Dose Schematic
Within a cohort, p articipants will be randomized to one of 3 treatment sequences such 
that each participant receives 2 active doses and 1 placebo dose resulting in each active 
dose being administered to 6 partic ipants and placebo to 3 participants
Starting dose (Dose 1) = 5mg
Subsequent dose escalations will be determined based on safety and PK data
Maximum predicted dose = 500 mg(Genotoxic Risk Assessment Limit= 3000mg)
Washout= 7 day s or 5 half -lives, which ever is longer
    = Dose escalation meeting
      PBO= Placebo
       *Note: dosing strategy is for illustrative purposes and does not represent the randomization 
strategy   
Part B: Single and Repeat Dose 7 or 14-day dose -rising
Figure 2 Repeat Dose Schematic (Part B)
Screening 
(~[ADDRESS_274041] dose)Follow-up 
(~[ADDRESS_274042] -
final dose per 
cohor t)Treatment Period
Cohor t B1, n=12 (9A :3P) Cohort  B2 n=12 (9A: 3P) Cohort B3, n=12 (9A:3P)
Dose [ADDRESS_274043]
                  Doses will be selected based on safet y, tolerability  and PK data from Part A
           = Dose escalation meeting
2018N361438_05 CONFIDENTIA L
209275
13Part C: Food Effect
Figure [ADDRESS_274044] Schematic ( Part C)
-7-day or 5 half-lives (whichever is longer) washout period/ participant crossover to 
fasted/fed arm
2018N361438_05 CONFIDENTIA L
209275
141.3. Schedule of A ctivities (SoA )
Part A -Single Dose 
ProcedureScreening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (for each dosi ng period) Follow -
up
(~14±[ADDRESS_274045] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 -1 1 2 34 E.D.
Informed consent X
Inclusion and 
exclusion criteria 
(including drug 
screens)X XRecheck clinical status before 
random ization and/o r 1st dose of 
study medication.
Demography X
Physical examination 
including height and 
weightF B B (B) FF: Full exam; B: Brief Exam; height 
is only taken once at screening
Medical history 
(includes substance 
usage and family 
history of premature 
cardiovascular (CV) 
disease and any 
changes in health 
status occurring 
between screening 
and admission to the 
unit)X XSubstances: Drugs, Alcohol, 
tobacco, and caffeine
Past and current 
medical conditions  X X
2018N361438_05 CONFIDENTIA L
209275
15Part A -Single Dose 
ProcedureScreening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (for each dosi ng period) Follow -
up
(~14±[ADDRESS_274046] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 -1 1 2 34 E.D.
Human 
Immunodeficiency 
Virus (HIV), Hepatitis 
B and C screeningXIf test otherwise performed within [ADDRESS_274047] dose of study 
intervention, testing at screening is 
not required
Admission to Clinical 
UnitX
Safety Laboratory 
assess ments 
(include liver 
chemistries)X X X X X X (X) XPredose; [ADDRESS_274048] -dose and at follow -up visit
Routine Urinalysis X X X X X (X) XPredose; [ADDRESS_274049] rocardiogram 
(ECG)X X ====================== X=====================  (X) XECGs assessed at screening 
(triplicate) and admission (single).  
During treatment period ECGs 
assessed predose (triplicate at least 
5 minutes (min) intervals) and 
single mea surements postdose 
every [ADDRESS_274050] -dose 
2018N361438_05 CONFIDENTIA L
209275
16Part A -Single Dose 
ProcedureScreening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (for each dosi ng period) Follow -
up
(~14±[ADDRESS_274051] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 -1 1 2 34 E.D.
Vital signs (pulse 
rate, blood pressure 
(bp), respi[INVESTIGATOR_697], 
and oral 
temperature)X X ====================== X==================== ==(X) XVitals assessed at screening 
(triplicate measurements for pulse 
and (bp)) (and admission (single 
measurements).  During treatment 
period vitals assessed predose 
(triplicate measurements for pulse 
and bp) and postdose (single 
measurements) ev ery [ADDRESS_274052] dose in period 1.
Genet ic sample XAny time predose on Day 1. 
This research may be described in 
a separate Informed Consent Form 
(ICF) or as part of a combined ICF.  
A separate signature [CONTACT_227572] X
2018N361438_05 CONFIDENTIA L
209275
17Part A -Single Dose 
ProcedureScreening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (for each dosi ng period) Follow -
up
(~14±[ADDRESS_274053] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 -1 1 2 34 E.D.
Telemetry XTelemetry performed starting 30 
min ( 10 min) pre -dose to 12 hr 
(20 min) post -dose
Adverse Event (AE) 
review======================= X====================  (X) X
Serious Adverse 
Event (SAE) reviewX =========== =========== =====X=== ============ ==============  (X) X
Concomitant 
medication reviewX
============ ==========X====== =============== (X) X
24hr urine sampling 
for 
Pharmacodynamics 
(PD)X1X2X3X3(X)1combined void for windows of [ADDRESS_274054]-dose 
3combined void for 24 hr
2018N361438_05 CONFIDENTIA L
209275
18Part A -Single Dose 
ProcedureScreening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (for each dosi ng period) Follow -
up
(~14±[ADDRESS_274055] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 -1 1 2 34 E.D.
Blood sampling for 
Pharmacokinetics 
(PK)============ ==========X====== ============ ===
(X)Predose, 5min, 30min, [ADDRESS_274056] -dose
Discharge from 
Clinical UnitX (X)
The timing and number of planned study  assessments, including safet y, PK, PD /biomarker or other assessments may  be altered 
during the course of the study  based on newl y available data (e.g., to obtain data closer to the time of peak plasma 
concent rations) to ensure appropriate monitoring. 
Any changes in the timing or addition of time points for any  planned stud y assessments as the result of emerging 
pharmacokinetic/pharmacody namic data from this study  must be documented and approved by  [CONTACT_46958] t study  team member and then 
archived in the sponsor and site study  files, but will not constitute a protocol amendment. The Competent Authority  (CA) and ethics 
committee (EC) will be informed of an y safety  issues that constitute a substantial amendment an d require alteration of the safety  
monitoring scheme or amendm ent of the ICF . The changes will be approved by  [CONTACT_227536]. 
2018N361438_05 CONFIDENTIA L
209275
19Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274057] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
Informed consent X
Inclusion and 
exclusion criteria 
(including dru g 
screens)X XRecheck clinical status 
before randomization and 
prior to muscle biopsy/or 
1st dose of study 
medication.
Demography X
Full physical 
examination including 
height and weightF B B (B) FF:Full exam; B: Brief exam; 
height is only taken once at 
screening
Medical history 
(includes substance 
usage and family 
history of premature 
CV disease and any 
changes in health 
status occurring 
between screening 
and admission to the 
unit)X XSubstances: Drugs, 
Alcohol, tobacco, and 
caffeine
Past and current 
medical conditions  X X
2018N361438_05 CONFIDENTIA L
209275
20Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274058] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –[ADDRESS_274059] 
dose of study interventi on, 
testing at screening is not 
required
Admission to Clinical 
UnitX
Safety Laboratory 
assessments (include 
liver chemistries)X X X X1X1X1X (X) X1Pre-randomization 
assessments for eligibility 
must be performed PRIOR 
to predose muscle biopsy
Predose, [ADDRESS_274060] -Day 1 dose; 
additional timepoints may 
be added based on findings 
in Part A
1Days 7, 11, 17 , 20, and 
follow -up
Routine urinalysis X X X X2X2X2X2
(X) X2Predose, [ADDRESS_274061] -Day 1 dose; 
additional timepoints may 
be added based on findings 
in Part A
2Days 7, 11,17, 20,and 
follow -up
2018N361438_05 CONFIDENTIA L
209275
21Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274062] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
Hormone monitoring X X (X)Samples to be taken at 
midnight and 9am ( 10 min) 
on Days -1 and 17 
Samples taken at midnig ht 
will be analysed for 
adrenocorticotropic hormone 
(ACTH) and cortisol
Samples taken at 9am will 
be analysed for ACTH, 
cortisol, luteinizing hormone 
(LH), follicle stimulating 
hormone (FSH), thyroid 
stimulating hormone (TSH), 
total testosterone, 
dihydrote stosterone (DHT), 
triiodothyronine (T3), and 
free thyroxine (free T4) 
See Section 8.2.7 for 
information regarding 
monitoring of abnormal 
hormone results
2018N361438_05 CONFIDENTIA L
209275
22Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274063] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
12-lead ECG X X =====X 5=====  X5X5X5X5X5(X) XECGs assesse d at 
screening (triplicate 
measure) and admission 
(single measure).  During 
treatment period ECGs 
assessed predose 
(triplicate measure at at 
least 5 min intervals) and 
post-dose (single measure) 
every [ADDRESS_274064]-dose at Cmax 
based on observed Cmax 
in Part A (currently 
estimated to occur at ~[ADDRESS_274065] dose) , except for Day 
20. Day 20 ECG to occur 
any time before Discharge
2018N361438_05 CONFIDENTIA L
209275
23Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274066] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
Vital signs (pulse 
rate, bp, respi[INVESTIGATOR_862], and oral 
temperature)X X X6X7X6(X) X6Vitals assessed at 
screening (triplicate 
measurements for pulse 
and bp) and admission 
(single measurements).  
During treatment period 
vitals assessed predose 
(triplicate measurements 
for pulse and bp) and 
postdose (single 
measurements) every [ADDRESS_274067] -
dose
7Vitals assessed once 
every 24 hr
See Section 8.2.2 for 
further information
Randomization X
2018N361438_05 CONFIDENTIA L
209275
24Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274068] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
Genetic sample XAny time predose on Day 1
This research may be 
described in a separate ICF 
or as part of a combined 
ICF.  A separate signature 
[CONTACT_227573] n is 
optional
Study intervention X
====================X====================== 
Telemetry XTelemetry performed 
starting 30 ( 10 min) pre -
dose to 12 hr ( 20 min) 
post-dose
AE review=============================X== ============================ 
SAE review =========================================X======================================== 
Concomitant 
medication review=========================================X======================================== 
2018N361438_05 CONFIDENTIA L
209275
25Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274069] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
Urine sampling PD X8X9X9X9, 10X9(X)8combined void for 
windows of [ADDRESS_274070]-dose 
10 Day 10 only
Aliquots will be removed 
prior to pooling for urine 
PK.Total urine volume will 
be recorded before aliquots 
for PD are removed .
2018N361438_05 CONFIDENTIA L
209275
26Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274071] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
24h urine sampling 
for PK and metabolite 
profilingX X X X (X)Voids from urine 
pharmacodynamic (P D) 
sampling windows will be 
combined into 0 -24 hr pools 
on Day -1,1, and 17 after 
aliquoting for PD. 
These voids will be 
combined for PK/metabolite 
analysis only after aliquots 
for urine PD are removed
See study reference 
manual (SRM) for details 
on sam ples and processing
2018N361438_05 CONFIDENTIA L
209275
27Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274072] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
Blood sampling for 
PKX11X12X12X12X11(X)11Day 1 and Day 17: 
Predose, [ADDRESS_274073] -dose
12pre-dose samples 
collected on days 6,7, 9 -11 
and 15 -16
Blood sampling for 
metabolite profilingX XDay 1 and Day 17: 
Predose, [ADDRESS_274074] -dose
Blood s ampling for 
Pharmacodynamics 
and biomarkersX13X13X14X14(X)13Predose and [ADDRESS_274075] -
dose on Day 1  
14Predose Days 10 and 17
2018N361438_05 CONFIDENTIA L
209275
28Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274076] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –1 1 2 3 4 5-7 8 9-11 12 13-14 15 16 17 18 19 20
Muscle Biopsy X15X16(X)Muscle biopsies must be 
performed AFTER clinical 
safety assessments on the 
corresponding days
15Day -[ADDRESS_274077] ion 
to be recorded. Muscle 
biopsy can be performed at 
any time during pre -dose 
period.
2018N361438_05 CONFIDENTIA L
209275
29Part B –Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (f or each dosing cohort) E.DFollow
-up
(~14±
[ADDRESS_274078] 
dose)Notes
E.D = early 
discontinuation/withdrawal –2 –[ADDRESS_274079] (bile 
sample collection)XFor second or third dose -
level only (depending on 
PK results in Part A)
Enterotest capsule to be 
swallowed ~2 hr after 
dosing and removed ~7 hr 
after dosing (~1 hr after 
food cue)
Enterotest food cue XFor second or third dose -
level only (depending on 
PK results in Part A)
Food cue will be given [ADDRESS_274080]-dose
Discharge from 
Clinical UnitX (X)
The time to start the second dose in Part B can be modified based on the estimates of half -life from Part A.
Duration of dosing in Part B can be modified based on the estimates of half -life from Part A.
2018N361438_05 CONFIDENTIA L
209275
30The timing and number of pla nned stud y assessments, including safet y, PK, PD /biomarker or other assessments may  be altered 
during the course of the study  based on newl y available data (e.g., to obtain data closer to the time of peak plasma 
concentrations) to ensure appropriate monito ring. 
Any changes in the timing or addition of time points for any  planned stud y assessments as the result of emerging 
pharmacokinetic/pharmacody namic data from this study  must be documented and approved by  [CONTACT_227537], but will not constitute a protocol amendment. The CA and ECwill be 
informed of an y safety issues that constitute a substantial amendment and require alteration of the safety monitoring scheme or 
amendmen t of the ICF . The changes will be approved by  [CONTACT_227538] d the EC before implementation.
2018N361438_05 CONFIDENTIA L
209275
31Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274081] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13
Informed consent X
Inclusion and 
exclusion criteria 
(including drug 
screens)X XRecheck clinical status before 
randomization a nd prior to muscle 
biopsy/or 1st dose of study 
medication.
Demography X
Full physical 
examination including 
height and weightF B B (B) FF: Full exam; B: Brief exam; height 
is only taken once at screening
Medical history 
(includes substance 
usage and family 
history of premature 
CV disease and any 
changes in health 
status occurring 
between screening 
and admission to the 
unit)X XSubstances: Drugs, Alcohol, 
tobacco, and caffeine
Past and current 
medical con ditions  X X
2018N361438_05 CONFIDENTIA L
209275
32Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274082] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –[ADDRESS_274083] dose of study 
intervention, testing at screening is 
not required
Admission to Clinical 
UnitX
Safety Laboratory 
assessments (include 
liver chemistries)X X X X1X1X1(X) X1Pre-randomization assessments 
for eligibility must be performed 
PRIOR to predose muscle biopsy
Predose, [ADDRESS_274084]-Day 1 dose; additional 
timepoints may be added based on 
findings in Part A
1Days 7, 10, 13, and follow -up
Routine urinalysis X X X X2X2X2(X) X2Predose, [ADDRESS_274085]-Day 1 dose; additional 
timepoints may be added based on 
findings in Part A
2Days 7, 10, 13, and f ollow -up
2018N361438_05 CONFIDENTIA L
209275
33Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274086] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13
Hormone monitoring X XSamples to be taken at midnight 
and 9am ( 10 min) on Days -1 and 
10
Samples taken at midnight will be 
analysed for adrenocorticotropic 
hormone (ACTH) and cortisol
Samples taken at 9am will be 
analysed for ACTH, cortisol, 
luteinizing hormone (LH), follicle 
stimulating hormone (FSH), thyroid 
stimulating hormone (TSH), total 
testosterone, dihydrotestosterone 
(DHT), triiodothyronine (T3), and 
free thyroxine (free T4) 
See Section 8.2.7 for information 
regarding monitoring of abnormal 
hormone results
2018N361438_05 CONFIDENTIA L
209275
34Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274087] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13
12-lead ECG X X =====X=====  X5X5X5(X) X5ECGs assessed at screening 
(triplicate measure) and admission 
(single measure).  During 
treatment period ECGs assessed 
predose (trip licate measure at at 
least 5 min intervals) and post -
dose (single measure) every [ADDRESS_274088]-dose at Cmax based on 
observed C max in Part A (currently 
estimated to occur at ~[ADDRESS_274089] 
dose) , except for Day 13 . Day 13 
ECG to occur any time before 
Discharge
2018N361438_05 CONFIDENTIA L
209275
35Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274090] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13
Vital signs (pulse 
rate, bp, respi[INVESTIGATOR_862], and oral 
temperature)X X X6X7X6(X) X6Vitals assessed at screening 
(triplicate measurements for pulse 
and bp) and admission (single 
measurements).  During treatment 
period vitals assessed predose 
(triplicate measurements for pulse 
and bp) and postdose (single 
measurements) every [ADDRESS_274091] -
dose
7Vitals assessed once every 24 hr
See Section 8.2.2 for further 
information
Randomization X
Genetic sample XAny time predose on Day 1
This resear ch may be described in 
a separate ICF or as part of a 
combined ICF.  A separate 
signature [CONTACT_227574]
2018N361438_05 CONFIDENTIA L
209275
36Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274092] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13
Study intervention X ==================X=================== 
Telemetry XTeleme try performed starting 30 
(10 min) pre -dose to 12 hr ( 20 
min) post -dose
AE review =========================================X========================================== 
SAE review ====================================================X============== ========================================== 
Concomitant 
medication review======================================================= =X================================================ 
2018N361438_05 CONFIDENTIA L
209275
37Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274093] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13
Urine sampling PD X8X9X9X9(X)8combined void for window s of [ADDRESS_274094]-dose 
Aliquots will be removed prior to 
pooling for urine PK. Total urine 
volume will b e recorded before 
aliquots for PD are removed .
2018N361438_05 CONFIDENTIA L
209275
38Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274095] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13
24h urine sampling 
for PK and metabolite 
profilingX X X (X)Voids from urine 
pharmacodynamic (PD) sampling 
windows will be combined into 0 -24 
hr pools on Day -1,1, and 10 after 
aliquoting for PD. 
These voids will be combined for 
PK/metabolite analysis only after 
aliquots for urine PD are removed
See study reference manual (SRM) 
for details on samples and 
processing
Blood sampling for 
PKX10X11X11X11X10(X)10Day 1 and Day 10 : Pre dose, [ADDRESS_274096]-dose
11pre-dose samples collected on 
days 6, 7, and 9
2018N361438_05 CONFIDENTIA L
209275
39Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274097] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –[ADDRESS_274098] -
dose
Blood sampling for 
Pharmacodynamics 
and biomarkersX12X12X13X13(X)12Predose and [ADDRESS_274099] -dose on 
Day 1  
13Predose Days 7 and 10
2018N361438_05 CONFIDENTIA L
209275
40Part B .2–7 Day Repeat Dose 
ProcedureScreeni
ng 
(up to 
30 days 
before 
Day 1)Intervention Period [Days] (for each dosing cohort) E.DFollow -
up
(~14±[ADDRESS_274100] 
dose)Notes
E.D = early 
discontinuation/withdrawal
–2 –1 1 2 3 4 5 6 7 8 9 10 11 12 13
Muscle Biopsy X14X15(X)Muscle biopsies must be 
performed AFTER clinical safety 
assessments on the corresponding 
days
14Day -[ADDRESS_274101] dose 
administered
Time of sample collection to be 
recorded. Muscle biopsy can be 
performed at any time during pre -
dose period.
Discharge from 
Clinical UnitX (X)
2018N361438_05 CONFIDENTIA L
209275
41The time to start the second dose in Part B can be modified based on the estimates of half -life from Part A.
Duration of dosing in Part B can be modified based on the estimates of half -life from Part A.
The timing and number of planned study  assessments, including safet y, PK, PD/biomarker or other assessments may  be altered 
during the course of the study  based on newl y available data (e.g., to obtain data closer to the time of peak plasma 
concentrations) to ensure appropriate monitoring. 
Any changes in the timing or addition of time points for any  planned stud y assessments as the result of emerging 
pharmacokinetic/pharmacody namic data from this study  must be documented and approved by  [CONTACT_227539], but will not constitute a protocol amendment. The CA and EC will be 
informed of an y safety issues that constitute a substantial amendment and require alteration of the safety monitoring scheme or 
amendment of the ICF. The changes will be approved by  [CONTACT_227538] d the EC before implementation.
2018N361438_05 CONFIDENTIA L
[ADDRESS_274102] 
Screening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (with or without food) Follow -
up
(~14±[ADDRESS_274103] 
dose)Notes
E.D = ear ly 
discontinuation/withdrawal–1 1 2 34 E.D.
Informed 
consentX
Inclusion and 
exclusion criteria 
(including drug 
screens)X XRecheck clinical status 
before randomization and/o r 
1st dose of study medication.
Demography X
Physical 
examination 
including height 
and weightF B B (B) FF: Full exam; B: Brief Exam; 
height is only taken once at 
screening
2018N361438_05 CONFIDENTIA L
[ADDRESS_274104] 
Screening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (with or without food) Follow -
up
(~14±[ADDRESS_274105] 
dose)Notes
E.D = ear ly 
discontinuation/withdrawal–1 1 2 34 E.D.
Medical history 
(includes 
substance 
usage and 
family history of 
premature CV 
disease and any 
changes in 
health status 
occurri ng 
between 
screening and 
admission to the 
unit)X XSubstances: Drugs, Alcohol, 
tobacco, and caffeine
Past and current 
medical 
conditions  X X
HIV, Hepatitis B 
and C screeningXIf test otherwise performed 
within [ADDRESS_274106] 
Screening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (with or without food) Follow -
up
(~14±[ADDRESS_274107] 
dose)Notes
E.D = ear ly 
discontinuation/withdrawal–1 1 2 34 E.D.
Safety 
Laboratory 
assessments 
(including liver 
chemistries)X X X X X X (X) XPredose; [ADDRESS_274108] -dose and at 
follow -up visi t
Routine 
UrinalysisX X X X X (X) XPredose; [ADDRESS_274109] -dose and at 
follow -up visit
12-lead ECG X X =========================== X===============================  (X) XECGs assessed at screening 
(triplicate) and admission 
(single ).  During treatment 
period ECGs assessed 
predose (triplicate at least 5 
min intervals) and single 
measurements postdose 
every [ADDRESS_274110] 
Screening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (with or without food) Follow -
up
(~14±[ADDRESS_274111] 
dose)Notes
E.D = ear ly 
discontinuation/withdrawal–1 1 2 34 E.D.
Vital signs (pulse 
rate, bp, 
respir atory rate, 
and oral 
temperature)X X ======================= X======================= 
(X) XVitals assessed at screening 
(triplicate measurements for 
pulse and bp) and admission 
(single measurements).  
During treatment period vitals 
assessed predose (triplicate 
measurements for pulse and 
bp) and postdose (single 
measurements) every [ADDRESS_274112] 
Screening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (with or without food) Follow -
up
(~14±[ADDRESS_274113] 
dose)Notes
E.D = ear ly 
discontinuation/withdrawal–[ADDRESS_274114] M eal XFed Arm only. See Section 
5.3.1 for timings regarding 
meals, fasting, and treatment 
administration
Study 
interventionX
Telemetry XTelemetry performed starting 
30 min ( 10 min) pre -dose to 
12hrs ( 20 min) post -dose
AE review =================== X===================  (X) X
SAE review X              =========== ========= ============X=== ============= ==============  (X)
Concomitant 
medication 
reviewX ============ ====== ========= =====X========= =====================  (X) X
Blood sampling 
for PK============ ==========X====== ===============  (X)Predose, [ADDRESS_274115] 
Screening 
(up to 30
days 
before Day 
1)Treatment Period [Days] (with or without food) Follow -
up
(~14±[ADDRESS_274116] 
dose)Notes
E.D = ear ly 
discontinuation/withdrawal–1 1 2 34 E.D.
Discharge from 
Clinical UnitX (X)
Duration of dosing in Part Ccan be modified based on the estimates of half -life from Part A.
The timing and number of planned study  assessments, including safet y, PK, PD /biomarker or other assessments may  be altered 
during the course of the study  based on newl y available data (e.g., to obtain data closer to the time of peak plasma 
concentrations) to ensure appropriate monitoring. 
Any changes in the timing or addition of time points for any  planned stud y assessments as th e result of emerging 
pharmacokinetic/pharmacody namic data from this study  must be documented and approved by  [CONTACT_227540], but will not constitute a protocol amendment. The CAand ECwill be informed of any  safet y 
issues that constitute a substantial amendment and require alteration of the safet y monitoring scheme or amendment of the ICF. The 
changes will be approved by  [CONTACT_227536].
2018N361438_05 CONFIDENTIA L
[ADDRESS_274117] time into human study  (FTIH) for [COMPANY_004]3439171A. The study  will 
evaluate the safet y, tolerability  and pharmacokinetics (PK) of single ascending and repeat 
oral doses of [COMPANY_004]3439171A in healthy  adult participants. A food effect asses sment will 
be undertaken using a crossover design to investigate the influence of food on the PK of 
[COMPANY_004] 3439171 A. Pharmacody namic (PD) and biomarker effects of [COMPANY_004]3439171A in 
healthy  adult volunteers will also be explored. The results of this study  are inte nded to be 
used to identify  appropriate and well tolerated oral doses to be used in further studies 
investigating [COMPANY_004] [ADDRESS_274118] s are 
involved.
2.2. Background
2.2.1. Hematopoietic prostaglandin D2 sy nthase (H -PGDS)
Figure 4 Prostanoid Sy nthesis
Prostaglandin D 2(PGD 2)is a downstream product of the arachidonic acid cascade 
(Figure 4) and is s ynthesized by  [CONTACT_227541] s [Lewis, 1982].  Other cells such 
as dendritic cells, T helper 2 (Th2) cells, and epi[INVESTIGATOR_227500] 2, but at 
lower levels than mast cells.  PGD 2mediates its effects via activation of the specific G -
protein coupled receptors DP1 [ Boie , 1995] and DP2 (CRTH2) [ Abe, 1999] and also acts 
via the receptor for thromboxane A2 (TXA 2), the TP receptor, on target c ells [ Hirata , 
2011].
2018N361438_05 CONFIDENTIA L
209275
49The cy clo-oxygenase (COX) enz ymes convert arachidonic acid in a two -step process, 
first to PGG 2and then to the unstable endoperoxide, PGH 2.  The PGD sy nthase (PGDS) 
enzy me is subsequentl y responsibl e for the catal ytic isomerization of PGH 2to PGD 2
[Smith , 2011].  PGD 2is generated b y the action of either H -PGDS (hematopoietic -type or 
H-type) or L -PGDS (lipocalin -type or L -type) enzy mes [ Urade , 2000]).   PGDS is the key  
regulator of PGD 2synthesis by  [CONTACT_227542] -presenting cells of the immune 
system, and orchestrates mechanisms of inflammation in muscle disorders (acute injury  
and chronic degenerative diseases), allergy  and a sthma.  Strong biological evidence 
demonstrates H -PGDS -mediated PGD 2production impairs skeletal muscle repair [ Mohri , 
2009], and blockade of this signal via gene manipulation, using knock -out (KO) mice, 
and small molecule inhibition of either H -PGDS or the PGD 2receptors DP1 and DP2 
accelerates the kinetics of muscle remodeling and functional recovery .  Additionally , 
tissue levels of H -PGDS and PGD 2are elevated in acutel y injured tissue and chronicall y 
inflamed tissue.  N otably, H -PGDS inhibitors increase markers of m yogenesis (My oD 
and my ogenin) following muscle injury  in animals.  Taken together, selective inhibition 
of H-PGDS offers potential to improve muscle adaptation, aiding recovery  from injury , 
for example during rehabilitation.
Importantly , other products of arachidonic acid metabolism such as PGE 2and PGF2α 
produce beneficial signaling in muscle [ Korotkova , 2014] and therefore approaches that 
decrease global inflammatory  sign aling (e.g. nonsteroidal anti -inflammatory  drugs, 
NSAIDs) are not efficacious.  This may  be especially  pertinent to populations recovering 
from surgical interventions involving tendons and associated structures, where NSAIDs 
can block tendon healing [ Cohen , 2006; Connizzo , 2014].
2.2.2. [COMPANY_004]3439171A
[COMPANY_004]3439171A is a potent, reversible, and highl y selective azetidine urea inhibitor of 
H-PGDS –the major enzyme responsible for the production of PG D2 in mast cells. All 
information regarding non-clinical safety  and pharmacology isavailable in the 
Investigator’s Brochure (IB) [GlaxoSmithKline Document Number 2018N359817_00 ]. 
[COMPANY_004]3439171A has not been previo usly administered to human participants; therefore, 
there are no clinical data available.
This first clinical study , which will constitute the initial administration to humans, will be 
conducted in healthy  human participants.
2.3. Benefit/Risk A ssessment
Consis tent with GlaxoSmithKline ([COMPANY_004]) guidance for earl y phase studies, 
[COMPANY_004]3439171A will be administered in an in -patient setting (with sufficient overnight 
facilities) in the [LOCATION_002] with appropriate monitoring.
In order to minimise the risk of the initi al human administration of [COMPANY_004]3439171A, a 
sentinel dosing strategy  will be utilized in each of the cohorts in Part A: [ADDRESS_274119]-dose, (or 5 
half-lives, whichever is longer )the remaining participants from that cohort will be dosed. 
2018N361438_05 CONFIDENTIA L
[ADDRESS_274120] -dose (or 5 half -lives, whichever is longer)
have been completed for a minimum of 4 participants on active treatment at each dose 
level, the [COMPANY_004] team and the investigator will review all of the available safety  and PK 
data from all participants before proceeding to the next dose level. 
Summaries of findings from non -clinical studies conducted with [COMPANY_004] 3439171 A can be 
found in the Inves tigator’s Brochure. The following section outlines the risk assessment 
and mitigation strategy  for this protocol:
2018N361438_05 CONFIDEN TIAL
209275
512.3.1. Risk A ssessment:
Potential Risk of Clinical 
SignificanceSummary of Data/Ration ale for Risk Mitigation Strategy
Investigational Product (IP) [e.g., [COMPANY_004]3439171A]
Potential effect on liver In adult dogs at oral doses levels up to 600 mg/kg/day for 
6 weeks, [COMPANY_004]3439171 was associated with minimal to 
slight changes in the liver (mixed periportal 
inflammatory  cell infiltrates at ≥100 mg/kg/day ) that 
generall y correlated with increases in serum ALT, 
glutamate deh ydrogenase (GLDH) and/or alkaline 
phosphatase (ALKP).  Mean serum levels were increased 
for ALT: 2.4 to 4.7 times, for GLDH: 2.6 to 4 times, and 
for ALKP: 1.[ADDRESS_274121] to 
magnitude, severit y and incidence. The dog liver finding 
is considered monitorable in clinical setting and not dose 
limiting. The high dose of 600 mg/kg/day  was associated 
with systemic exposure AUC (0 -t)of 57.8 µg.h/mL in 
male dogs.The stoppi[INVESTIGATOR_227501]:
Elevatio n of alanine aminotransferase 
(ALT) and other liver tests (aspartate 
aminotransferase [AST], bilirubin [total and 
direct])
Potential effect on e ndocrine 
system (adrenal gland)In juvenile rats, recoverable, dose responsive findings 
were noted in the a drenal gland (cortical hy pertrophy  of 
the zona fasciculata) with associated increased adrenal 
weights, pale discoloration and/or enlargement in males 
given ≥100 mg/kg/day  and females given ≥10 
mg/kg/day .  As the findings may  beconsidered 
potentially adver sefor repeat clinical dosing , the no 
adverse effect level (NOEL ) for adrenal gland histologic The AUC stoppi[INVESTIGATOR_227502] 
11µg.hr/mL for the repeat dose phase is 
below (0.24 times) the lowest effect 
exposure for rat adrenal toxicity  and 
participants will be monitored at tim es 
indicated in the SoA for changes in the 
following levels:
2018N361438_05 CONFIDEN TIAL
209275
52Potential Risk of Clinical 
SignificanceSummary of Data/Ration ale for Risk Mitigation Strategy
effects was 1 0mg/kg/day  in male and female rats, with 
associated AUC (0-t)of 3.94µg.h/mL . The lowest 
individual AUC at lowest effected dose level (LOEL )of 
100 mg/kg/day  for male juvenile rat adrenal effects is
46µg.h/mL .  adrenocorticotropic hormone (ACTH), 
cortisol
luteinizing hormone (LH), 
follicle stimulating hormone (FSH), 
thyroid stimulating hormone (TSH)
total testosterone
dihydrotestosterone (DHT)
thyroxine (T4) 
triiodothy ronine (T3) 
Potential effect on female 
reproductive tissuesIn female juvenile rats, recoverable, dose responsive 
microscopic findings were also noted in the ovary  
(vacuolation of interstitial cells) and mammary  gland 
(lobuloalveolar hypertrophy /hyperplasia) at ≥100 
mg/kg/day ; and pi[INVESTIGATOR_2117]  (increased mitoses of cells in 
the pars distalis) at 600 mg/kg/day .  All women will be excluded from this study .
The nonclinical toxicology  and 
efficacy  studies were 
conducted using 
non-micronized material, while The rat and dog toxicity  studies with non -micronized 
material attained AUC and Cmax exposures substantially  
over the NOAE L to effectively  characterize the 
nonclinical safet y of [COMPANY_004]3439171.  Additionally, the Conservative assumptions were used for the 
minimum anticipated biological effect level 
(MABEL )simulations and the predictions 
for the first dose are expected to be well 
2018N361438_05 CONFIDEN TIAL
209275
53Potential Risk of Clinical 
SignificanceSummary of Data/Ration ale for Risk Mitigation Strategy
this clinical study  will use 
micronized, thus there is a risk 
that the clinical PK will be 
different than predictedimpurity  profile of the micronized material was 
consistent with that of the non -micronized material.  
Thus, the nonclinical safety  data is considered supportive 
of clini cal use of micronized compound.below the dog NOAEL exposure margins, 
110-and 270 -fold lower for AUC(0 -inf) and 
Cmax, respectively . 
The suspension used for non -clinical studies 
was homogenised and the particle size thus 
reduced smaller than non -micronised.  
Solubility  does not change on micronisation 
but in -vitro bio -relevant dissolution data 
shows a proportional response in rate of 
dissolution for non -micronised, ground and 
micronized. 
Study Procedures
Entero -Test
Streaks of blood on the string 
due to local irritation have 
been infrequentl y noted. 
Rarel y, a patient will be unable 
to sw allow the capsule because 
of gagging or will vomit after 
doing so. Gagging upon 
retrieval of the string can 
occur. On a few occasions, an 
entire string has been 
swallowed without ill effects The use of Entero -Test has been approved 
by [CONTACT_1622] (510(k), Summary  of safety  and 
effectiveness). The string will be securel y 
taped in place during the collection time to 
minimize r isk of swallowing the entire 
string. An y subject incapable of swallowing 
the capsule will be allowed to participate in 
the study  without duodenal bile collection.
2018N361438_05 CONFIDEN TIAL
209275
54Potential Risk of Clinical 
SignificanceSummary of Data/Ration ale for Risk Mitigation Strategy
and passes from the bod y in the 
feces. Consider risks associated 
with comparators, challenge 
agents, imaging agents, 
medical devices, etc
Muscle Biops y
Localized pain from muscle 
biopsy  procedure can occur
Low risk of bleeding or 
infection could occur as result 
of the procedure. There is a 
very low risk of nerve damage 
as a result of the procedureLocal anesthetic will be employ ed during 
muscle biopsy  procedures.
Acetaminophen or another medication 
selected b y the investigator and the medical 
monitor can be administered to participants 
to control post -procedural pain.
Biopsy  procedure will be performed b y staff 
experienced in the technique. Participants 
will be followed up for any  adverse events 
resulting from the biopsy and m anaged 
appropriatel y, if needed.
2018N361438_05 CONFIDENTIA L
209275
552.3.2. Benefit A ssessment
There will be no benefit to the participant taking part in this study . However, participants 
will be contributing to the process of developi[INVESTIGATOR_227503] b y taking part in the 
study .
2.3.3. Overall Benefit :Risk Conclusion
The measures taken to minimize the potential risks identified in association with 
[COMPANY_004]3439171A are considered sufficient to justify participation by  [CONTACT_227543].
3. OBJECTIVES A ND ENDPO INTS
Objectives Endpoints
Primary
To assess the safet y and 
tolerability  of [COMPANY_004]3439171A 
following single and repeat doses in 
healthy  participants
To characterize the PK of 
[COMPANY_004]3439171A, following single 
and repeat doses in healthy  
participantsAdverse events (AE), clinical 
laboratory  values, vital si gns, and 
electrocardiograms (ECG)
Derived PK parameters for 
[COMPANY_004]3439171A including area 
under the plasma drug concentration 
versus time curve (AUC(0 -t), 
AUC(0 -inf), maximum observed 
plasma drug concentration (C max), 
time to maximum observed plasma 
drug con centration (t max), and 
apparent terminal half -life (t 1/2) as 
appropriate
Secondary
To assess the effect of food on the PK 
of [COMPANY_004]3439171A following an oral 
dose in healthy  participants 
To assess preliminary  dose 
proportionality  of [COMPANY_004]3439171A Derived PK parameters for 
[COMPANY_004]3439171A including area under 
the plasma dr ug concentration vers us 
time curve (AUC(0 -t), AUC(0 -inf), 
maximum observed plasma drug 
concentration (Cmax), time to 
maximum observed plasma drug 
concentration (tmax), and apparent 
terminal half -life (t 1/2) as appropriate
AUC(0 -t), AUC(0 -inf), and Cmax 
following single dose and AUC(0 -τ) 
2018N361438_05 CONFIDENTIA L
209275
56Objectives Endpoints
follow ing single and re peat oral doses, 
as data permit
To examine the extent of accumulation 
and achievement of steady -state 
following repeat oral doses of 
[COMPANY_004]3439171A, as data permitsand Cmax following repeat dose for 
the assessment of dose proportionality
Determine observed accumulation 
based on AUC(Ro) and Cmax 
(RCmax) and determine the stead y-
state ratio (Rss) 
Trough plasma concentrations at the
end of the dosing interval (C τ) 
collected pre -dose for repeat doses 3, 
4, 12,13 and 14 (repeat doses 3,4,6, 
and 7 for 7 day  dosing) to assess the 
achievement of stead y-state of 
[COMPANY_004]3439171A 
Exploratory
To evaluate the PD properties of 
[COMPANY_004]3439171A
To assess the effect of 
[COMPANY_004] 3439171 Aon QTc in healthy  
adult volunteers
To evaluate additional biomarkers 
of [COMPANY_004]3439171A target 
engagement after single and repeat 
doses.
To investigate the plasma, urinary  
and biliary  (Part B) metabolic 
pathway s of [COMPANY_004]34391 71A in 
healthy  subjectsLevels of mediators on 
prostaglandin and/or inflammatory
metabolic pathway ssuch as, but not 
limited to, PGD2, andPGE2 .
Holter monitor data collection and 
storage for evaluation of the 
correlation between plasma levels 
of [COMPANY_004] 3439 171Aand changes in 
the QTc interval in the future, if 
appropriate
Levels of change in novel 
biomarkers in blood, muscle, or 
urine, such as, but not limited to, 
urine tetranor PGDM and PGEM 
(tPGDM, tPGEM), PGD2, and 
PGE2
[COMPANY_004]3439171 A-related material in 
plasma, urine and bile .
2018N361438_05 CONFIDENTIA L
209275
574. STUDY DESIGN
4.1. Overall Design
This is a three -part study  (Parts A, B and C).  Part A will be a double -blind (sponsor 
unblinded), single oral dose, dose -rising, placebo -controlled, randomized (with respect to 
placebo allocation), 3 pe riod crossover study  in approximately 3 cohorts of participants.  
Part B will be double -blind (sponsor unblinded), up to 1 4day repeat oral dosing, placebo -
controlled, randomized (with respect to placebo allocation), dose escalation study  with at 
least thr ee dose levels in 3 separate cohorts of participants who were not enrolled into 
Parts A or C of this study.  Part C will be an unblinded, randomized, crossover study  
where a single dose will be administered fasted or fed conducted in a separate cohort of 
participants than those who were enrolled in Parts A or B. 
The starting dose for Part A will be 5 mg (see Section 4.3.3 ). 
Part A: Single Ascending Dose 
Each participant will participate in 3 dosing periods andwill receive 2 doses of 
[COMPANY_004]3439171A and 1 dose of placebo in a randomized fashion.  There will be an 
approximately 7day(or 5 half -lives, whichever is longer) washout period between 
dosing in each session.
Approximately  [ADDRESS_274122] -dose (or 5 
half-lives, whichever is longer) .  Ad ditional participants may  be dosed at a given level if 
additional data are necessary  to establish safet y, tolerability  or PK parameters prior to 
dose escalation.
Each active dose level will be administered initially to a smaller group of participants (1 
onactive and 1 on placebo) to evaluate safet y at each dose level. These sentinel 
participants will be followed clinicall y for 48 hr ( or 5 half -lives, whichever is longer )to 
allow for adequate observation of safet y (given a predicted half -life of 6.1 hr for
[COMPANY_004]3439171A) after dose administration to monitor for emergence of adverse events.  If 
no acute safet y issues are observed in this smaller group of sentinel participants 
(including review of 48 hr safet y laboratory  results), then the remaining participant s 
(approximately  5 participants on active and 2 participants on placebo) will receive this 
2018N361438_05 CONFIDENTIA L
209275
58same dose prior to dose escalation. See S ection 6.6for information on the decision to 
proceed to the next dose level.
Part B: Single and Repeat D oseup to 14-day dose -rising
In each cohort of Part B of the study , approximately  twelve participants will be 
randomized to either one dose level of [COMPANY_004]3439171A or placebo according to a 
randomization schedule prepared prior to th e start of the study .  The study  will be 
conducted sequentially  starting with Dose 1 Cohort B1. Participants will receive repeat 
daily  or twice dail y (BID)doses of the stud y intervention or placebo based on ongoing 
PK data obtained in Part sAand B .
Parti cipants will report to the Clinical Research Unit on Day  -2 and will remain in the 
unit for the duration of Part B. Participants will randomly  be assigned to receive a single 
dose (or a BID dose depending on data obtained in Part A) of [COMPANY_004]3439171A or place bo 
(approximately  9 study  intervention : 3 placebo).   Plasma and urine PK, PD, and 
biomarker samples (including a pre -dose muscle biopsy ) will be collected for up to 72hr 
after initial dosing. After completion of assessments at 72hr(Day  4), participants will 
begin a repeat dosing regimen consisting of one dose (or a BID dose depending on data 
obtained in Part A) per day  for up to 14 days. This time period is based on a predicted 
half-life of [COMPANY_004]3439171A of 6.1 hours (with a range of 4 -22 hours) calculated from 
preclinical data and is designed to allow [COMPANY_004]3439171A to reach stead y state during the 
dosing period. The actual repeat dose duration can be altered based on PK data in Part A 
of the study .  For example, if the predicted half -life is confirmed from P art A of the study  
then the duration of dosing in Part B will be much shorter to achieve steady -state than 
planned currentl y. Dosing duration in Part B and follow -up will be shortened 
appropriatel y based on emerging PK data from Part A. Participants will b e discharged on 
the morning of Day 13 ([ADDRESS_274123] dose during the 7 day  repeat dose period) or Day 
20(3days post -last dose during the 14 day  repeat dose period ) following completion of 
study  assessments, including a post -dose muscle biopsy .  Safet y, tolerability  and PK data 
review for a minimum of 6 participants receiving active treatment will be carried out 
upon completion of assessments on Day 13 or 20(72hours post -last dose) before 
initiation of dosing in the next cohort.  The dose of [COMPANY_004]343917 1A may  be adjusted 
(lower or higher) based on data from Part A and for cohorts going forward based upon 
the safet y, tolerability , PK, and preliminary  PD data from the previous cohort. 
All participants will return to the clinical unit for a follow -up visit approximately  [ADDRESS_274124] dose of study  medication.  
Part C: Food Effect
In this crossover design, approximately  12 participants will take part in two
approximately 4-day study  sessions with dosing in each session sep arated by  
[CONTACT_3450]  7 days(or 5 half -lives of the study  intervention, whichever is longer) .  In 
each stud y session, participants will be admitted to the clinical unit and receive a single 
dose of [COMPANY_004]3439171A either in the fasted state or after a high fat meal. Participants will 
be randoml y assigned to one of two treatment sequences in a two -period crossover design 
(fed/fasted or fasted/fed). The timing of assessments in Part C can be altered based upon 
data obtained in Parts A and B.
2018N361438_05 CONFIDENTIA L
[ADDRESS_274125] dose of study  medication.
The total duration of the study  for each participant recruited into Part A will be 
approximately  10weeks. For participants recruited into Part B, the total study  duratio n 
will be up to approximately  9weeks.  For participants recruited into Part C, the total 
study  duration will be up to approximately  8 weeks.  
4.2. Scientific Rationale for Study  Design
The FTIH study  with [COMPANY_004]3 439171A will evaluate the safety  of [COMPANY_004] 3439171 A in 
healthy  participants in order to avoid confounding factors due to the disease or 
concomitant drugs in patients. The study  design is based on pre -clinical findings for 
[COMPANY_004] 3439171 A, contributing to the frequency , type and duration of safet y assessment and 
monitoring during treatment periods in each cohort.
The single dose assessments in Part A will be conducted to determine safet y, tolerability , 
PK, and PD o f the study  intervention in individuals before progressing to doses explored 
further in other parts of the study . The sequential design of the single dose components 
will allow for dose escalation to occur approximately  every  two weeks with a 7-day 
period of washout.  This approach allows for any  adjustments needed based on emerging 
safet y, tolerabilit y, and PK information. The crossover design within each cohort in Part 
A is preferred as it allows for each participant to serve as their own control for the 
assessment of safet y and provides PK assessment in the same individual at two different 
dose levels, reducing the influence of inter -individual variability .
In Part B, a single dose safet y, tolerability  and PK will be collected followed by  
[CONTACT_227544] t hese participants to the repeat dose portion of the study . The 7 or 14-day 
dosing was chosen as it is thought to provide sufficient safet y and tolerability  data to 
bridge to longer duration studies. The dosing period can be adjusted depending on PK 
and PD data collected in Part A of the study .
Prostaglandin species, particularl y prostaglandin D2, are virtually undetectable in the 
blood or plasma of unchallenged and/or otherwise healthy  human subjects. However, 
skeletal muscle contains high levels of prost anoids in the basal state, and our preclinical 
data reveal significant dose -dependent reductions in prostaglandin D2 levels in skeletal 
muscle following administration of H -PGDS inhibitors [[COMPANY_004]3439171A I nvestigator’s 
Brochure] . Therefore, muscle biopsies w ill be performed both pre -and post -study  
intervention in Part B to assess the effect of [COMPANY_004]3439171A on prostanoid levels in situ in 
a tissue of potential clinical interest .
During preclinical pharmacokinetic assessments, [COMPANY_004]3439171A was found to be highl y
bioavailable (generall y >40%); however, recovery of [COMPANY_004]3439171A in urine was low 
(<2% of the administered dose) [ [COMPANY_004]3439171A Investigator’s Brochure] .In order to 
characterize potential biliary  elimination pathway s, this study  will also employ  the 
2018N361438_05 CONFIDENTIA L
[ADDRESS_274126] string is expected following one dose of 
the study  drug, this assessment will be restricted to only one cohort in Part B (anticipated 
to be the second or third dose level depending on PK results in Part A )at participants’ 
last dose .  In addition, uri ne will be collected and used to investigate the urinary  
elimination of parent drug and an y metabolites alongside bile anal ysis as well as anal ysis 
of PK samples for drug and metabolites (under a separate protocol ).
Additionally , Holter monitor data will b e collected and stored for a future evaluation of 
the correlation between plasma levels of [COMPANY_004]3439171A and changes in the QTc interval, 
if appropriate.
The crossover design for assessing the effect of food on [COMPANY_004]3439171A in Part C allows   
each participant to serve as their own control, reducing the influence of potential inter -
individual variability  in this part of the study .
The 7 -day(or 5 half -lives, whichever is longer) washout utilized in Parts A and C of the 
study  is believed to provide sufficient wa shout based on preclinical data and simulations 
but can be modified based on emerging data in Part A.
4.3. Justification for Dose
Dose selection of [COMPANY_004]3439171A for this FTIH study  was based on NOAEL data in the 
most sensitive spe cies, predicted PK of humans usi ng the PK data from preclinical 
species, and a target therapeutic exposure based on the in -vitro H -PGDS recombinant 
enzy me assay , and in -vivo dose -response evaluation of [COMPANY_004]3439171A in wild -type 
(WT) eccentric damage and dy strophin deficient (mdx) mouse mo dels. 
The human PK parameters were calculated from preclinical mouse, rat, dog and monkey  
data. A range of human clearance and volume of distribution values were estimated by  a 
variet y of liver blood flow (LBF), allometric scaling, and Ph ysiologicall y Based PK 
(PBPK) methods using GlaxoSmithKline software package PK Predictor Pro version 
[IP_ADDRESS], Excel and GastroPlus 9.0, respectively . Human bioavailability  was estimated by  
[CONTACT_227545], rat, dogs, and monkey s and estimated fr om 
LBF and single species scaling. Based on allometry  and LBF, the predicted median 
human clearance was 10.8 mL /min/kg. The predicted median (range) human volume of 
distribution was 4.6 L /kg (3.2 -6.0) and the predicted median (range) of half -life was 6.1 h
(4-22). The human oral absorption rate was assumed to be 6.0 h-1, based upon the average 
of the preclinical species (7.5 h-1). The predicted oral bioavailability  median (range) was 
61% (39% -68%). A 100% bioavailability  can be used as a conservative approa ch.
[COMPANY_004]3439171 was given orally  to adult dogs for 6 weeks, and rats for 8 weeks starting 
dosing as juveniles on Postnatal Day  (PND) [ADDRESS_274127] in the dog (inflammatory  cell infiltrates in 
2018N361438_05 CONFIDENTIA L
209275
61periportal region) which was associated with elevations in liver enzy me activity , and 
adrenal gland and female reproductive tissue effects in the juvenile rat. In both species 
there was a sex difference in sy stemic exposure, with the females generally  having higher 
exposure. For dogs with liver findings that were associated with increases in alanine 
aminotransferase activity (ALT), glutamate deh ydrogenase (GLDH) or alkaline 
phosphatase (ALKP) activity , findings were dose and exposure -responsive with re spect 
to magnitude, severit y and incidence. Mixed inflammatory  cell infiltrates in the liver 
combined with the increases in liver -related enzymes were considered adverse at 
≥100 mg/kg/day ; thus, the NOAEL in dogs for 6 weeks duration was considered to be 
20mg/kg/day with females having higher exposure (AUC: 11.0µg.h/mL ).Since the dog 
liver finding is monitorabl e in a clinical setting and not considered dose limiting, the 
male exposure at 600mg/kg/day  (AUC: 57.8 g.h/mL )is considered acceptable asa 
clinical single exposure limit for Part A.In juvenile rats, recoverable, dose -responsive 
findings were noted in the adrenal gland (cortical hy pertrophy  of the zona fasciculata) 
with associated increased adrenal wei ghts, pale discoloration and/or enlargement in males 
given ≥100 mg/kg/day  and females given ≥10 mg/kg/day .At 10 mg/kg, 1 of 10 female 
rats had pale discoloration and an increased adrenal gland weight, without a microscopic 
change. The rat adrenal finding s may be considered potentially  adverse, the NOEL for 
adrenal gland histologic effects was 1 0mg/kg/day  in male and female rats, with 
associated AUC (0 -t) of 3.94 µg.h/mL .The lowest individual AUC at the lowest effected 
dose level (LOEL) of 100 mg/kg/day  for male juvenile rat adrenal effects is 46 µg.h/mL .  
In a preliminary  study , there were no adrenal macroscopic or microscopic effects in adult 
male r ats after 7 day s of dosing 1000 mg/kg/day (AUC in blood: 1130 µg.h/mL ).  
In female juvenile rats, recove rable, dose responsive microscopic findings were also 
noted in the ovary  (vacuolation of interstitial cells) and mammary  gland (lobuloalveolar 
hypertrophy /hyperplasia) at ≥100 mg/kg/day ; and pi[INVESTIGATOR_2117]  (increased mitoses of cells in 
the pars distalis) at 60 0 mg/kg/day .  
Results of other nonclinical studies suggest that [COMPANY_004]3439171 does not present a 
genotoxic risk to humans. Additionally , there were no safet y pharmacology findings of 
clinical concern at oral dog doses up to 1500 mg/kg. There were no chang es considered 
related to [COMPANY_004]3439171 administration in the evaluation of sper matogenesis in either 
species. Thus, the nonclinical data support the conduct of clinical studies in men up to 
6weeks duration up to the mean s ystemic exposure at the NOEL for adr enal gland 
histologic effects in the rat study  (AUC: 3.94 g.h/mL ) with appropriate monitoring in 
place , and for a shorter duration of 7 day s up to the dog liver NO AEL exposure (AUC: 
11.0 µg.h/mL ).  
Based on in vivo efficac y studies and mechanism of the H-PGDS pathway , the efficacy  
target was to maintain [COMPANY_004]3439171A concentrations above the IC 50. A 10% inhibition of 
the H -PGDS enzy me (IC 10) was considered as the minimal anticipated biological effect 
level (MABEL). The IC50 and I C10were calculated from the H-PGDS recombinant 
enzy me inhibition assay  and compared with in vivo studies (dy strophin deficient (mdx) 
and WT eccentric damage mouse models).
[COMPANY_004]3439171A in vitro inhibition was evaluated using a recombinant human H -PGDS 
enzy me assay . The data was fitte d using an E max model and the IC50was 7. 77ng/mL and 
2018N361438_05 CONFIDENTIA L
209275
62the IC10was 0.86 ng/mL. The target IC 50was compared to the in vivo efficacy  studies in 
the WT eccentric damage mouse model and a d ystrophin deficient (mdx) mouse model 
which is a commonly  used preclin ical model to mimic Duchenne muscular dy strophy . In 
these models, the corresponding ED 50(0.7 mg/kg/day and 0.6 mg/kg/day , respectivel y) 
and I C50(5.5 ng/mL and 4.7 ng/mL, respectivel y) were comparable . Briefl y, in these 
studies, 8-month old male mice were administered an initial dose of vehicle or 0.1, 0.3, 
1.0, 3.0, 10 and 30 mg/kg of [COMPANY_004]3439171A 10 minutes prior to a challenge of 60 
eccentric contraction repetitions, and then daily  (BID, per oral ( PO)) administration 
thereafter for 46 day s. On day  45, se rial blood samples were collected from a subset of 
animals (n=3) in each dose group and the stead y state pharmacokinetic parameters were 
estimated. At vary ing intervals, maximal isometric limb torque was measured in vivo to 
assess functional recovery . Wher eas vehicle -treated mdx mice exhibited prolonged 
recovery  kinetics and never fully reached their starting (B aseline) function (~30% 
permanent force deficit), [COMPANY_004]3439171A -treated animals recovered significantly  faster 
with significantl y greater resolution o f their force deficit. In the efficacy  studies, 
longitudinal composite of muscle function pre -damage, and intermittently  throughout the 
46-day study  was obtained. [COMPANY_004]3439171A provided a significantl y protective effect to 
the initial insult at doses ≥1 mg/k g. Limb recove ry over time was normalized to B aseline 
from day  [ADDRESS_274128] to 
calculate an ED50 of 0.6 mg/kg/day  with a 95% confidence interval ranging from 0.14 –
2.8 mg/kg/day . Thus, based on the H-PGDS enz yme inhibition evaluation, the target IC 50
and I C10values were 7. 77ng/mL and 0.86 ng/mL, respectivel y. 
PK simulations (100 replicates) were performed in a 70 -kg human using an estimated 
median clearance (10.8 mL/min/kg ) and volume of distribut ion (4.6 L /kg) with 30% 
between -subject variability  assuming a 1 -compartment model. Based on the results, a 37 
mg BID dose would achieve concentrations greater than the target I C50in more than 90% 
of patients.
4.3.1. Maximum Recommended Starting Dose (MRSD)
Usin g the FDA Guidance for estimation of the maximum safe starting dose, the NOAEL 
in female dogs was converted to the Human Equivalent Dose (HED) based on body  
surface area. After apply ing an uncertainty  safet y factor of 10 (guideline default) to the 
HED, the maximum recommended starting dose for a 60 -kg adult is 66.7 mg. 
4.3.2. Dose Predicted to A chiev e the Therapeutic Exposure Target
The primary  in vivo efficacy  study  was a dose -response evaluation of [COMPANY_004]3439171A on 
the H -PGDS recombinant enzy me and compared with data from the in vivo studies of 
muscle repair following injury  in the mdx, WT eccentric damage mice.  Based on the 
predicted human clearance value range of 5.7-19.5 mL /min/kg , a preclinical exposure 
target of 0.176 μg·h/mL and a conservative oral bioavailability  range of 39% to 100%, 
the dose to achieve the therapeutic exposure target ranged from [ADDRESS_274129] conservative estimates, this AUC(0 -t) value (0.176 μ g·h/mL) is63-fold and 328-
fold lower than the AUC(0 -t) value offemale dog NOAEL and single dose stoppi[INVESTIGATOR_227504], respectively .The predicted Cmax value from the 37 mg (higher dose: Pred 
2018N361438_05 CONFIDENTIA L
209275
63Cmax=0. 0925 g/mL) is about 29-fold and 108-fold lower than the Cmax value of 
NOAEL and single dose stoppi[INVESTIGATOR_227505] , respectively .
Assumptions were made on the following PK and PD parameters in order to bridge from 
animal to man: CL , V, F and in vivo ED 50of H-PGDS. These assumptions will be 
verified with lower dose data and if needed, adjustments will be made in subsequent dose 
selections.
4.3.3. Minimum A nticipated Biological Effect Level (MA BEL) Dose
A 10% inhibition of the H -PGDS enzy me (I C10) was considered as the MABEL and the 
PK of lower [COMPANY_004]3439171A was simulated in a 70 -kg human using an estimated median 
clearance ( CL)(10.8 mL/min/kg ) and V (4.6 L /kg) with 30% between -subject variability  
assuming a 1 -compartment model. A single dose of 5 mg was predicted to maintain IC10
levels (0. 86ng/mL) and a reasonable concentration is expected to be above the lower 
limit of quantification (LLOQ).  This predicted AUC(0 -t) value for 5 mg dose (0.1 
μg·h/mL) is 110 -fold lower than the NOAEL AUC(0 -t) value and the predicted Cmax 
value (0.01 μg/mL ) is about 270 -fold lower than the NOAEL Cmax value.
4.3.4. Dose Predicted to A chiev e Exposure at the NOA EL Dose Level 
and Single Dose Stoppi[INVESTIGATOR_227506] 5.7 -19.5 mL/min/kg , a 
conservative range of oral bioavailability  from 39% to 100%, and a NOAEL AUC(0 -t) 
value of 11μg·h/mL , the dose to achieve the female dog NOAE L exposure level ranges 
from 263to 2310 mg. Also, the dose to achieve the Single Dose Stoppi[INVESTIGATOR_227507] 57.8 μg·h/mL ranges from 1384 to 12138mg.
4.3.5. Summary
The MRSD is 66.7 mg, the dose to achieve t he therapeutic target is 37 mg BID, and dose 
to achieve the female dog NOAEL exposure level ranges from 263 to 2310 mg. Based on 
MABEL dosing, the starting dose will be 5 mg (13.34 -fold lower than M RSD). Further 
dose escalation will be based on exposure, s afety, and tolerability  from the previous dose 
level. Based on the range of predicted H -PGDS inhibition and NOAEL  exposure cover, 
the expected top dose may  be500mg and the maximum dose that can be administered 
based on the Genotoxic Risk Assessment (GRA) is [ADDRESS_274130] completed the study  if he/she has completed all 
phases of the stud y includi ng or the last scheduled procedure shown in the SoA.
The end of the stud y is defined as the date of the last visit of the last participant in the 
study .
2018N361438_05 CONFIDENTIA L
209275
645. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrolment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply :
Age
1.Participant must be 18 to 65years of age inclusive, at the time of signing the 
informed consent.
Type of Participant and Disease Characteristics
2.Participants who are overtly  health y as determined by [CONTACT_227546] , phy sical examination, laboratory  tests, and cardiac monitoring. A 
participant with a clinical abnormality  or laboratory  parameter(s) not specifically  
listed in the exclusion or exclusion crit eria that is outside the reference range for the 
population being studied may  be included onl y if the investigator, in consultation 
with the Medical Monitor, agree and document that the finding is unlikel y to 
introduce additional risk factors and will not interfere with the stud y procedures.
Weight
3.Body weight ≥50.0 kg (110 lbs. ) and body  mass index (BMI) within the range 18.5 
to 31.0 kg/m2(inclusive).
Sex
4.Only  males are eligible for this study
Contraceptive use should be consistent with local regulations regarding the methods of 
contraception for t hose participating in clinical studies.
Male participants are eligible to participate if they  agree to the following during their 
entire enrolment in the study  plus an additional 5 day s or 5 terminal half -lives (whichever 
is longer)
Refrain from donating sperm
PLUS either:
Be abstinent from sexual intercourse as their preferred and usual lifesty le 
(abstinent on a long term and persistent basis) and agree to remain abstinent 
OR
Must agree to use contraception/barrier as detailed below 
female partner to us e an additional highl y effective contraceptive method
with a failure rate of <1% per year as described in Appendix 4.
2018N361438_05 CONFIDENTIA L
209275
65Informed Consent
5.Capable of giving signed informed consent as described in Appendix 1 which 
includes compliance with the requirements and restrictions listed in the I CFand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.History  or presence of cardiovascular, respi[INVESTIGATOR_696] , hepatic, renal, gastrointestinal, 
endocrine, hematological, or neurological disorders capable of significantl y altering 
the absorption, metabolism, or elimination of drugs; constituting a risk when taking 
the stu dy intervention; or interfering with the interpretation of data .
2.Any clinically  significant abnormal vital signs
3.Lym phoma, leukemia, or any  malignancy  within the past [ADDRESS_274131] bee n resected with no 
evidence of metastatic disease for 3 years
4.Alanine transaminase (ALT) >1.5x upper limit of normal (ULN) 
5.Bilirubin >1.5xUL N (isolated bilirubin >1.5xULN is acceptable if bilirubin is 
fractionated and direct bilirubin <35%). 
6.Current or c hronic history  of liver disease, or known hepatic or biliary  abnormalities 
(with the exception of Gilbert's s yndrome or as ymptomatic gallstones)
7.QTc >450 msec
NOTES:
The QTc is the QT interval corrected for heart rate according to Fridericia’s 
formula (QTc F), machine -read or manually  over -read.
The specific formula that will be used to determine eligibility  and 
discontinuation for an individual subject should be determined prior to initiation 
of the study . In other words, several different formulae cannot b e used to 
calculate the QTc for an individual subject and then the lowest QTc value used 
to include or discontinue the subject from the trial.
Prior/Concomitant Therapy
8.Unable to refrain from the use of aspi[INVESTIGATOR_248], NSAIDs , vitamins, herbal and dietary  
supplem ents (including St John’s Wort) within [ADDRESS_274132] dose of 
study  medication (Specific medications listed in Section 6.5may be allowed).
2018N361438_05 CONFIDENTIA L
209275
66Prior/Concurrent Clinical Study Experience
9.Where participat ionin the study  would result in loss of blood or blood products in 
excess of [ADDRESS_274133] 30 day s before signing of 
consent in this or any  other clinical study  involving an investigational study  
intervention or an y other type of medical research. 
Diagnostic assessments
12.Presence of Hepatitis B surface antigen (HBsAg) at screening 
13.Positive Hepatitis C antibody  test result at screening.
NOTE:  Subjects with positive Hepatitis C antibody due to prior resolved disease can be 
enrolled, only  if a confirmatory  negative Hepatitis C ribonucleic acid ( RNA )test is 
obtained
14.Positive Hepatitis C RNA test result at screening or within [ADDRESS_274134] 
dose of study  intervention
NOTE: Test is optional and subjects with negative Hepatitis C antibody  test are not 
required to also undergo Hepatitis C RNA testing
15.Positive pre -study  drug/alcohol screen
16.Positive h uman immunodeficiency virus (HIV) antibody  test
Other Exclusions
17.Regular use of known drugs of abuse or positive urine drug test at screening or each 
in-house admission to the clinical research unit
18.Regular alcohol consumption within 6 months prior to scre ening and 5 day s prior to 
admission defined as: 
An average weekl y intake of > 14 units f or males .  One unit is equivalent to 8 g 
of alcohol: a half -pi[INVESTIGATOR_11731] (~240 mL ) of beer, 1 glass (125 mL ) of wine or 1 (25 mL ) 
measure of [ADDRESS_274135] indicative of smoking history at screening or each in -
house admission to the clinical research unit or regular use of tobacco -or nicotine -
containing products (e.g. nicotine patches or vaporizing devices) within [ADDRESS_274136] yle Considerations
5.3.1. Meals and Dietary  Restrictions
Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit 
juice, pomelos, exotic citrus fruits, grap efruit hy brids, or fruit juices from 7 day s
before the start of stud y intervention until after the final dose.
In Parts A a nd B , participants will fast at least [ADDRESS_274137] -dosing. Meal times should be approximately  uniform 
across all treatment periods. See the study  reference manual (SRM) for additional 
details.
Water is al lowed as desired except one hour before and after dosing.
In Part B, a subset of participants will undergo biliary  metabolism testing using the 
Enterotest. The string device will b e swallowed approximately  [ADDRESS_274138] -dose 
(i.e. ~1 hour prior to string withdrawal), a food cue will be used to stimulate gall 
bladder empt ying and to encourage the release of bile onto the string:
Participants will be provided with visual images of food and aske dto 
imag ine eating the food for approximately  60 seconds.
Participants will then sniff a pi[INVESTIGATOR_227508]/zest for 
approximately  30 seconds.
Participants will consume a high -fat food morsel (e.g. sausage 
sandwich) in order to stimulate gallbladder contraction
Additional details on this procedure are available in the SRM
In Part C, participants will be fed a standard FDA high fat/high calorie meal after at 
least 8 hours of fasting and completion of pre -dose assessments ( see Table 1for a 
description of the standard FDA high fat/high calorie meal.) . The meal will be 
provided approximately  [ADDRESS_274139] consume the entire meal in 3 0 minutes or less. Non -
compliance will be recorded as well as the amount of the meal not eaten .   
The high fat/high calorie meal provided in the Fed arm of Part C should derive 
approximately  150, 250, and [ADDRESS_274140] FDA  High Fat, High Calorie Diet
Food Quantity Carbohydrate 
(g)Protein 
(g)Fat (g) Calories
2 eggs fried in 
butter2 eggs / 1 tsp 
butter1.2 12.6 10 + 
7.[ADDRESS_274141] 2 slices 30 5 2 180
Pats of butter 2 tsp 0 0 15.2 136
Total 58.2 36.6 53.8 920
5.3.2. Caffeine, A lcohol, and Tobacco
During each dosing session, participants will abstain from ingesting caf feine -or 
xanthine -containing products ( e.g., coffee, tea, cola drinks, and chocolate) for 24 
hours before the start of dosing until after collection of the final PK and/or PD
sample.
During each dosing session, participants will abstain from alcohol for 2 4 hours 
before the start of dosing until after collection of the final PK and/or PD sample. 
Participants will refrain from smoking or using tobacco or nicotine -containing 
products from at least [ADDRESS_274142] blood 
sample collected.
5.3.3. Activity
Participants will abstain from strenuous exercise for 72hours before each admission 
to the unit and throughout their stay  in the unit . Participants may  participate in light 
recreational activities during studies ( e.g., watching television, reading). Participants 
will also abstain from strenuous exercise for 72 hours before their follow -up visit.
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl y entered in the study . A minimal set of screen failure information 
is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries fr om regulatory  authorities. Minimal information includes 
demograph y, screen failure details, eligibility  criteria, and an y serious adverse events 
(SAE s).
Individuals who do not meet the criteria for participation in this study  (screen failure) 
may be rescre ened only if the reason for screen failure is an ECG or lab value that, in the 
opi[INVESTIGATOR_11922]/or Medical Monitor, is spurious or needs to be 
reconfirmed. Rescreened participants should be assigned a new participant number.
2018N361438_05 CONFIDENTIA L
[ADDRESS_274143] number and rescreening will 
only be needed if they  are outside the screening window.
6. STUDY INTERVENTION
Study  interventio nis defined as an y investigational intervention (s), marketed product(s), 
placebo ,or medical device (s)intended to be administered to a study  participant according 
to the study  protocol.
6.1. Stud y Intervention( s)Administered
ARM Name [CONTACT_227575]3439171A Placebo
Type Drug Drug
Dose 
FormulationOral solution (doses 0.5 mg up to 4.5
mg) 
capsule (doses 5 mg and upwards)Oral solution to match experimental
(doses 0.5 mg up to 4.5mg)
capsule (doses 5 mg and upwards)
Unit Dose 
Strength(s)TBD N/A
Dosage Level(s) 0.5 mg to not greater than 3000 mg 
(based on GRA limits) once or twice 
dailyDosage and frequency to match 
experimental
Route of 
Administrationoral oral
IMP and NIMP IMP NIMP
Sourcing Provided centrally by [CONTACT_227547], will be 
provided in amber glass bottles with a 
child resistant cap . Each amber glass 
bottle will be labeled as required per 
country requirement.
Study Inter vention for capsules, will be 
provided in HDPE bottles with a child 
resistant cap . Each HDPE bottle will be 
labeled as required per country 
requirement.Study Intervention for solutions, will 
be provided in amber glass bottles 
with a child resistant cap . Each 
amber glass bottle will be labeled as 
required per country requirement.
Study Intervention for capsules, will 
be provided in HDPE bottles with a 
child resistant cap . Eac h HDPE 
bottle will be labeled as required per 
country requirement.
2018N361438_05 CONFIDENTIA L
209275
706.2. Preparation/Han dling/Storage/A ccountability
Details on storage, handling, and allowable excursions for [COMPANY_004]3439171A investigational 
product ( IP), placebo, and solutions are provided in the Technical Agreement.
1.A description of the detailed methods and materials required f or preparation of 
[COMPANY_004]3439171A solution or capsule and placebo are provided in the Technical 
Agreement .
2.The solution and capsules will be extemporaneously  prepared at the clinical site as 
per instructions in the Technical Agreement that will be reviewed an d approved b y 
[COMPANY_004] prior to use.
3.The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention received and any  
discrepancies are reported and resolved before use of the study  intervention.
4.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(man ual or automated) area in accordance with the labeled storage conditions with 
access limited to the investigator and authorized site staff.
5.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability , reconciliation, and record 
maintenance ( i.e., receipt, reconciliation, and final disposition records).
6.Further guidance and information for the final disposition of unused study  
intervention are provided in the Technical Agreemen t.
Under normal conditions of handling and administration, study  intervention is not 
expected to pose significant safet y risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the ca se of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or 
[COMPANY_004] study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
Precaution will be taken to avoid direct contact [CONTACT_227548].  A MSDS
describing occupational hazards and recommended handling precautions will b e provided 
to the investigator. In the case of unintentional occupational exposure notify the monitor, 
Medical Monitor and/or [COMPANY_004] study  contact.
2018N361438_05 CONFIDENTIA L
209275
716.3. Measures to Minimize Bias: Randomization and Blinding
6.3.1. Randomization
Study using 
Pre-Coded 
Randomization 
provide d to siteBefore treatment begins at the beginning of each part of the study , participants will be 
assigned a unique number (randomization number) in a scending numerical order at the
study site. The randomization number encodes the partici pant’s assignment tothe 
respective arms of the study, according to the randomization schedule generated prior to 
the study by [CONTACT_227549]. Each participant will be dispensed 
blinded study intervention , labeled with his/her unique randomizatio n number throughout 
the study.
In Part A, approximately  9 participants in each cohort will be randomized to one of 3 
treatment sequences (AAP, APA & PAA, where A represents an active dose of 
[COMPANY_004] 3439171 and P represents placebo).   Within each period, allo cation of active (A) to 
placebo (P) treatment will be 2:1.   Within a cohort, an increasing dose of [COMPANY_004]3439171 A
will be administered in each period as illustrated in the table below. Planned doses are 
provided in S ection 6.6.   At each dose level, sentinel dosing will be employ ed, such that 
one subject is dosed with placebo and another with active dose of [COMPANY_004]3439171 Aand 
followed for 48hrprior to the rest of the subjects receiving their randomized treatment.
Cohort Sequence Period 1 Period 2 Period 3
Cohort 1 AAP
APA
PAAD1
D1
PlaceboD2
Placebo
D2Placebo
D3
D3
Cohort 2 AAP
APA
PAAD4
D4
PlaceboD5
Placebo
D5Placebo
D6
D6
Cohort 3 AAP
APA
PAAD7
D7
PlaceboD8
Placebo
D8Placebo
D9
D9
In each cohort of Part B, approximately 12 participants will be randomized to receive 
either [COMPANY_004]3439171 Aor placebo in a parallel design using a 3:1 allocation ratio. 
Participants will receive a single dose followed b y a 72hr assessment period and then 
will receive daily  repea t doses until the end of the study .
2018N361438_05 CONFIDENTIA L
209275
72Dose 
CohortRegimen
B1 R1 mg [COMPANY_004]3439171A or placebo QD or BID
B21R2 mg [COMPANY_004]3439171A or placebo QD or BID 
B31R3 mg [COMPANY_004]3439171A or placebo QD or BID 
1.Dose levels for Cohorts will be determined based on real -time ana lysis of the safety, 
tolerability, PK, and preliminary PD data from Part A and therefore may be adjusted from 
predicted dose levels listed.
QD–Once daily
BID-Twice daily
Regimen Period 1 Period 2
X [COMPANY_004]3439171A 1administered in the fasted 
state[COMPANY_004]343 9171A 1administered after a high 
fat meal
Y [COMPANY_004]3439171A 1administered after a high fat 
meal[COMPANY_004]3439171A 1administered in the fasted 
state
1 Dose to be determined based on data from Part A of the study
In Part C, approximately  12 participants will be rand omized 1:1 to receive 
[COMPANY_004]3439171A in one of two treatment sequences (Fed then Fasted or Fasted then Fed).
Participants who do not complete the study  may  be replaced at the discretion of the 
investigator in consultation with the sponsor.
6.3.2. Blinding
Blind Brea k 
(Envelopes)A sealed envelope that contains the study intervention assignment for each 
participant will be provided to the investigator. The sealed envelope will be 
retained by [CONTACT_093] (or representative) in a secured area.
In case of an emergen cy, the investigator has the sole responsibility for 
determining if unblinding of a participant’s treatment assignment is warranted.
Participant safety must always be the first consideration in making such a 
determination. If the investigator decides tha t unblinding is warranted, the 
investigator should make every effort to contact [CONTACT_31820] a 
participant’s treatment assignment unless this could delay emergency 
treatment of the participant. If a participant’s treatment assignment is unblind ed 
[COMPANY_004] must be notified within [ADDRESS_274144] be recorded in the source 
documentation and electronic case report form ( eCRF ), as applicable.
Once the study is complete, all envelopes ( sealed and opened) must be 
inventoried and returned to [COMPANY_004].
2018N361438_05 CONFIDENTIA L
209275
73A participant may  continue in the study  if that participant’s intervention assignment is 
unblinded.  
Participants will be randomized to receive study  intervention . Investigators and all site 
staff with the exception of the pharmacy  staff will remain blinded to each partic ipant’s 
assigned stud y intervention throughout the course of the study . In order to maintain this 
blind, unblinded site pharmacy  staff will be responsible for the dis pensation of all study  
intervention and will endeavour to ensure that there are no differences in time taken to 
dispense following randomization. The site staff will instruct the participant to avoid 
discussing the taste, dosing frequency , or packaging of the stud y intervention with the 
investigator.
Unblinded monitors and, in the event of a Quality  Assurance audit, the auditor(s), will be 
allowed access to un -blinded study  intervention records at the site to verify  that
randomization/dispensing has been done accurat ely.
A participant will be withdrawn if the participant’s treatment code is unblinded by  [CONTACT_227550]. The primary  reason for discontinuation (the event or 
condition which led to the unblinding) will be recorded in the eCRF.
[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind the 
intervention assignment for any  participant w ith an SAE. If the SAE requires that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of the 
report, id entify ing the participant’s intervention assignment, may  be sent to investigators 
in accordance with local regulations and/or [COMPANY_004] policy .
Members of the [COMPANY_004] clinical study  team will be unblinded for dose -escalation data 
reviews. This team may  include but i s not limited to the study  statistician, programmers, 
physician project leader, Muscle Metabolism Discovery  Performance Group leader, 
Clinical I nvestigation Lead, Operations Science Lead ,Data Qualit y Lead, 
pharmacokineticist, DMPK analy st, safet y review t eam, and other decision makers.  At 
the time of the data reviews, access to the randomization will be restricted to 
randomization numbers that have been assigned to participants in the cohort(s) under 
review.
6.4. Stud y Intervention Compliance
When the individu al dose for a participant is prepared from a bulk supply , the 
preparation of the dose will be confirmed b y a second member of the stud y site staff. 
When participants are dosed at the site, they  will receive study  intervention directly  
from the investigato r or designee, under medical supervision.  The date and time of 
each dose administered in the clinic will be recorded in the source documents.  The 
dose of study  intervention and study  participant identification will be confirmed at 
the time of dosing b y amember of the study  site staff other than the person 
administering the stud y intervention .  Study  site personnel will examine each 
participant’s mouth to ensure that the study  intervention was ingested.
2018N361438_05 CONFIDENTIA L
209275
746.5. Concomitant Therapy
Any medication or vaccine (inclu ding over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrollment or receives during the stud y must be recorded along with:
reason for use
dates of administration including sta rt and end dates
dosage information including dose and frequency
The Medical Monitor should be contact[CONTACT_43205] y questions regarding 
concomitant or prior therapy .
Participants must abstain from taking prescri ption or nonprescription drugs, includi ng 
vitamins and dietary  or herbal supplements (including St. John’s Wort) within 10 days (or 
14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whichever is longer) 
before the start of stud y intervention until completion of the follow -up visit, unless, in the 
opi[INVESTIGATOR_110409], the medication will not interfere with the study . 
Due to potential effects on [COMPANY_004]3439171A’s related pathway s, neither aspi[INVESTIGATOR_227509] y kind are permitted for use from 10 day s prior to the start of the study  
through the follow -up visit. Acetaminophen or another medication selected by  [CONTACT_227551] (acetaminophen 
not to exceed 4,000 mg/24 hrper current guidelines) by [CONTACT_227552] y.Local anaesthesia will be used for muscle biops y
procedures. Other concomitant medication may  be considered on a case -by-case basis by  
[CONTACT_227553] .
6.6. Dose Modification
This protocol allows some alteration from the currently  outlined dosing schedule, number 
of participants, and number of cohorts needed based on the emerging safet y, PK, and PD 
data, but the maximum daily  dose and/or (predicted) maximum/cu mulative exposure will 
not exceed 3000 mg (based on GRA limit), 57.8 µg·h/ml  for single dose AUC exposure 
limit in Part A (based on  liver effects in dog at 600 mg/kg male dog), or 11.0µg·h/ml for 
repeat dose AUC exposure limit in Part B (based on mean N OAEL exposure for liver
effects in 20 mg/kg female 6-week dogstudy ) respectivel y.  The AUC stoppi[INVESTIGATOR_227510] 11 µg.hr/mL  s for the repeat dose phase were set b y the rat adrenal toxicity  is 
below (0.24 times) the lowest effect exposure for rat adr enal toxicity  
Information regarding dose escalation review processes is detailed in the Dose Escalation 
Plan. Briefl y, the [COMPANY_004] medical monitor, in joint discussion with the participating 
investigato r(s) (to remain blinded during the stud y), will be respo nsible for making dose 
escalation decisions. Prior to the dose escalation decision, the [COMPANY_004] clinical team, which 
includes but is not limited to, the medical monitor, clinical scientists, safety ph ysician
and/or representative , and clinical pharmacokinetici st, will review critical safet y data 
defined in Section 8.2, Section 8.3, and in the Dose Escalation Plan. This includes review 
of all adverse events including non -dose-limiting toxicities, laboratory  assessments and 
2018N361438_05 CONFIDENTIA L
209275
75other defined safet y evaluations, as well as PK and PD data when appropriate. Qualit y 
control of critical safet y data will also be described in the Dose Escalation Plan, which 
includes ongoing stud y monito ring visits, Sponsor review of the clinical database, and 
confirmation b y site investigators and/or delegates that the data are accurate and 
complete.
The dose -escalation decision and rationale for each cohort will be discussed with the 
investigator(s) dur ing teleconference(s) and documented in writing, with copi[INVESTIGATOR_227511].
The decision to proceed to the next higher dose level will be made b y the clinical study 
team in consultation with the investigator(s) based on the evaluation of data from at least 
4 participants (Part A) or 6 participants (Part B) who received active treatment at the 
preceding lower dose.  Such decisions will be based on the safety  and tolerability , as well 
as PK data observed at the low er dose level and the predicted exposure at the next dose 
level.  Some doses may  be deleted and intermediate and/or higher/lower doses may  be 
added as appropriate during the stud y as the results of safet y/tolerabilit y, PK, and PD 
assessments become availab le.
The details on the dose escalation committee can be found in Section 9.5.1
6.6.1. Dose Escalation in Part A
In Part A, the decision to proceed to the next dose level of [COMPANY_004]3439171A will be made 
based on evaluation of the safet y, tolerability  and preliminary  PK data as outlined in 
Section 4.1.
The primary  preclinical exposure parameter that will guide dose escalation in Part A is 
based on single dose exposure limit inthe male dog at 600 mg/kg/day  (AUC(0 -24h)) at 
steady  state –57.8 µg.h/mL described in Section 4.3. Assuming time -invariance, the Day 
1 AUC(0 -inf) observed in each of the human participants in this study  at each sin gle dose 
will be compared to the above value in order to determine the magnitude of dose 
escalation. 
The following algorithm will be used for dose escalation in Part A:
1.For each dose group, the human mean AUC (0 -inf) on Day  1 will be calculated as 
percent age of the male dog at 600 mg/kg/day  of AUC(0 -24) steady -state ( 57.8
µg·h/mL). Example dose escalation based on single dose exposure limit exposures is 
provided below.  Some of the above doses may  be deleted and intermediate and/or 
higher doses may  be adde d as appropriate during the study  as the results of 
safet y/tolerability  and PK assessments become available. The next dose level can 
then be determined as described in the example table below :
2018N361438_05 CONFIDENTIA L
209275
76Table 2 Mean simulated exposures at SD of [COMPANY_004]3439171A  compared to 
single dose exposure limit set by  [CONTACT_227554] 600 mg/kg/day  
exposures levels
Dose 
(mg)Mean 
Simulated 
AUC (0-inf)
(μg*h/mL)Fold cover 
from 600mg/kg 
male dog 
AUC (0-24)1Mean 
Simulated 
Cmax
(μg/mL)Fold cover 
from 600
mg/kg male 
dog Cmax1Simulated % H -
PGDS inhibition 
maintained for24 
hours2
5 0.10 578 0.01 1000 10
20 0.39 158 0.05 200 20
50 0.99 58 0.12 83 40
100 1.97 29 0.24 42 60
300 5.91 10 0.72 14 80
500a9.85 6 1.20 8 85
1 Com pared tosystemic exposure at600 mg/kg/dayin male dog steady -state AUC(0 -24) and Cma x 
values ( 57.8 μg*h/mL and 10μg/mL, respectively)
2Represents the simulated mean [COMPANY_004]343171A concentrations maintained at different H-PGDS 
inhibition levels over [ADDRESS_274145] predicted mean Day  1 AUC (0 -inf) in Part A will not exceed 57.8
μg·h/ml.
Dosing in Part C (food effect) can be initiated after the exposures achieved with at least 
two dose levels administered in a fasted state are calculated. The dose levels chosen for 
Part C will ensure an adequate safety  margin to allow for an increased exposure of 
[COMPANY_004]3439171 A in the presence of food.
6.6.2. Dose escalation in Part B
Part B can be initiated after the safet y and P K data of at least four dose levels from Part A 
are evaluated. The decision to initiate Part B will be made b y the clinical study team in 
conjunction with the investigator. 
Dose selection in Part B will be based on the safety /tolerabilit y and PK data from Part A. 
The following rules will guide dose selection in Part B:
1.The starting daily  dose in Part B will be selected such that its predicted exposure 
(mean AUC(0 -24) and Cmax) on the last day of dosing is no higher than the Day [ADDRESS_274146] day of dosing (as a result of accumulation), this approach would select a daily 
dose which provides blood concentrations that, at any time during the period of 
dosing, are no higher than the ones alread y found to be well tolerated and had no 
safet y signals of concern in Part A. The expected exposure on the last day of dosing 
2018N361438_05 CONFIDENTIA L
[ADDRESS_274147] predicted mean AUC(0 -24) on the last day of dosing in Part B will not 
exceed 11.0μg·h /ml(based on mean NOAEL exposure for liver effects in 20 mg/kg 
female 6-week dogstudy and is below (0.24 times) the lowest effect exposure for rat 
adrenal toxicity ).
6.7. Intervention after the End of the Study
Not applicable.
7. DISCONTINUA TION OF STUDY IN TERVENTION A ND 
PARTICIPA NT DISCONTI NUA TION/WITHDRA WAL
7.1. Discontinuation of Study  Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention. If stud y intervention is permanentl y discontinued, the participant will
remain in the study and followed appropriately  until resolution of the event or return of 
labs to acceptable levels .See the SOA for data to be collected at the time of 
discontinuation of study  intervention.
7.1.1. Liver Chemistry Stoppi[INVESTIGATOR_227512] a participant if liver chemistry  stoppi[INVESTIGATOR_118048]:
2018N361438_05 CONFIDENTIA L
209275
78Phase I Liver Chemistry Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_227513] 
*INR value not applicable to subjects on anticoagu lants ALT ≥3xULN No
Yes
Must  refer to Liver Safety Requir ed Actions and Follow up Asses sments  section in the Appendi x
Repor t as an SAE if possibl e Hy’sLaw case:  ALT≥3xUL N and  Biliru bin≥2xUL N (>35% direct)  or 
INR>1.5*
Abbreviations: ALT = alanine transaminase; INR = international normalized rat io; SAE = serious adverse 
event; ULN = upper limit of normal.
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix [ADDRESS_274148] b een designed to assure 
participant safety  and evaluate liver event etiology .
Discontinuation of study  intervention for abnormal liver tests is required when:
a participant meets one of the conditions outlined in the algorithm
OR
when in the presence of abn ormal liver chemistries not meeting protocol -specified 
stoppi[INVESTIGATOR_004], the investigator believes stud y intervention discontinuation is in 
the best interest of the participant. 
[IP_ADDRESS]. Study  Intervention Restart or Rechallenge after liver stoppi[INVESTIGATOR_227514].
7.1.2. QTc Stoppi[INVESTIGATOR_2121]
TheQTcF formula must be used for each individual participant to determine 
eligibility  for and dis continuation from the study .  This formula may  not be changed 
or substituted once the participant has been enrolled.
2018N361438_05 CONFIDENTIA L
209275
79For example, if a participant is eligible for the protocol based on QTcF, then 
QTcFmust be used for discontinuation of this individual par ticipant as well.
TheQTcF formula must be used for a participant for all QTc data being 
collected for data analysis .  Safety  ECGs and other non -protocol specified 
ECGs are an exception.  
The QTc should be based on the average of triplicate ECG readings obtained over a 
brief (e.g., 5 -10 minute) recording period.  
A participant that meets either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from study  intervention.  
QTcF > 500 msec,
Change from B aseline: QTc >60 msec
See the SoA for data to be collected at the time of intervention discontinuation and 
follow -up and for an y further evaluations that need to be completed.
7.1.3. Individual Stoppi[INVESTIGATOR_2121]
Any participant who experiences an SAE will be withdrawn from the study .  
Any participant who experiences an AE of moderate or severe intensit y(as 
defined in CTCAE v5.0) that is considered attributable to dosing with 
[COMPANY_004]3439171A will be withdrawn from the stud y.  
7.1.4. Dose A djustment/Discontinuation Pharmacokinetic Criteria
In part A, a ny participant with observed AUC(0 -inf) or Cmax values greater than the 
mean stead y-state AUC(0 -24) and Cmax values in male dog ( 57.8 µg·h/mL and 10
ug/mL, respectivel y) will be discontinued from study  intervention .
In Part B, an y participant with observed AUC(0 -24) value greater than  the mean steady -
state AUC(0 -24) observed in female dogs (11.0µg·h/mL ) will be discontinued from study  
intervention .
See the SoA for data to be collected at the time of treatment discontinuation and follow -
up and for a ny further evaluations that need to be completed.
7.1.5. Temporary  Discontinuation
Temporary  discontinuation of the study  intervention is not allowed. 
7.1.6. Study Stoppi[INVESTIGATOR_2121]
[IP_ADDRESS]. Safety  Study  Stoppi[INVESTIGATOR_227515] n to higher doses will be stopped if 
either of the following occurs in the current dose group:
2018N361438_05 CONFIDENTIA L
209275
80An SAE that is considered to be related to [COMPANY_004]3439171A in one or more 
participants on active treatment.
Similar AEs of moderate or severe intensity (as defined i n CTCAE v5.0) that are 
considered to be related to [COMPANY_004]3439171A in two or more participants on active 
treatment.
Dosing at the current (or higher) dose may  resume only  if a safet y review conducted b y 
[COMPANY_004] in conjunction with the investigator determines that the observed SAEs or AEs are 
not related to [COMPANY_004]3439171 and such resumption is approved b y the IRB/IEC.
[IP_ADDRESS]. PK Study  Stoppi[INVESTIGATOR_227516](0 -24)from the 600 mg/kg/day  
male dog due to liver findings. It is plann ed that for Part A, the predicted human mean 
[COMPANY_004]3439171A AUC(0 -inf) or Cmax values will not exceed the mean [COMPANY_004]3439171A 
steady -state AUC(0 -24) and Cmax values in male dog (57.8 ug·h/mL  and 10 ug/mL, 
respectivel y). 
The repeat dose PK stoppi[INVESTIGATOR_227517](0 -24)from the 20mg/kg/day  
female dogNOAEL due to liver findings. It is planned that for Part B, the predicted 
human mean [COMPANY_004]3439171A  AUC(0 -24), value will not exceed the mean 
[COMPANY_004]3439171A stead y-state AUC(0 -24) values in dogat 20mg/kg/day of 11.0ug·h/mL.
7.2. Participant Discontinuation /Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, 
or may  be withdrawn at any  time at the discretion of the investigator for safety , 
behavioral, compliance o r administrative reasons. This is expected to be 
uncommon.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation 
visit should be conducted, as shown in the SoA. See SoA for data to be collected 
at the time of study  discontinuat ion and follow -up and for an y further 
evaluations that need to be completed.
The participant will be permanentl y discontinued both from the study 
intervention and from the study  at that time.
If the participant withdraws consent for disclosure of future in formation, the 
sponsor may  retain and continue to use any  data collected before such a 
withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site 
study  records.
7.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site. 
2018N361438_05 CONFIDENTIA L
[ADDRESS_274149] be taken if a par ticipant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact [CONTACT_43207]/or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee 
must make every  effort to regain contact [CONTACT_6635] (where possible, 3 
telephone calls and, if necessary , a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact [CONTACT_19425]’s medical record.
Should the participant continue to be unreacha ble, he/she will be considered to 
have withdrawn from the study . 
Discontinuation of specific sites or of the study  as a whole are handled as part of 
Appendix 1 .
8. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and th eir timing are summarized in the SoA. 
Protocol waivers or exemptions are not allowed 
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or 
discontinue st udy intervention .
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligib ility criteria. The investigator will maintain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clin ical management ( e.g., 
blood count) and obtained before signing of ICF ma y be utilized for screening or 
Baseline purposes provided the procedure met the protocol -specified criteria and was 
performed within the time frame defined in the SoA.
The maximum amo unt of blood collected from each participant over the duration of 
the study , including an y extra assessments that may  be required, will not exceed 500 
mL.
Repeat or unscheduled samples may  be taken for safet y reasons or for technical 
issues with the sample s.
8.1. Efficacy  Assessments
Not applicable.
2018N361438_05 CONFIDENTIA L
209275
828.2. Safet y Assessments
Planned time points for all safety  assessments are provided in the SoA.
8.2.1. Physical Examinations
A full physical examination will include, at a minimum, assessments of the 
Skin, Cardiovascular, Respir atory , Gastrointestinal and Neurological s ystems. 
Height and weight will also be measured and recorded (height is only  measured 
at screening) .
A brief ph ysical examination will include, at a minimum, assessments of the 
skin, lungs, cardiovascular s ystem, a nd abdomen (liver and spleen).
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
8.2.2. Vital Signs
Oral temperature, pulse rate, respi[INVESTIGATOR_2842], and blood pressure will be 
assessed.
Blood pressure and pulse mea surements will be assessed with a completel y 
automated device. Manual techniques will be used only  if an automated device 
is not available.
Blood pressure and pulse measurements should be preceded b y at least [ADDRESS_274150] ina supi[INVESTIGATOR_227518] a quiet setting without 
distractions ( e.g., television, cell phones).
Vital signs will be measured in a supi[INVESTIGATOR_55848] [ADDRESS_274151] readings should be averaged to give the 
measurement to be recorded in the case report form ( CRF ).
8.2.3. Electrocardiograms
Triplicate 12-lead ECG will be obtained as outlined in the SoA (see Section 1.3) 
using an ECG machine that automatically  calculate s the heart rate and measures 
PR, QRS, QT , and QTc intervals. Refer to Section 7for QTc withdrawal criteria 
and additional QTc readings that may  be necessary .
ECGs will be recorded whilst the participant is in a supi[INVESTIGATOR_2547], having 
rested in this position for at least 15 minutes.  Participants are permitted to make 
intermittent movement, if necessary , in preparation for procedures (e.g., to sit up 
to take study  medication).  When ECGs are to be taken in triplicate, an interval 
ofat least 5minutes will be used between measures taken at screening or pre -
dose.  An interval of at least [ADDRESS_274152] -dose triplicate 
ECGs, when needed.
2018N361438_05 CONFIDENTIA L
209275
83Various values from the ECG read -out will be entered into the eCRF (the 
average for some will be used for measures made in triplicate).
Any result falling outside the expected normal ranges as defined by  [CONTACT_227555].  If any  results falling outside of 
these expected normal ranges at the site are deem ed not clinically  significant by  
[CONTACT_227556] y qualified designee, then this should be 
clearl y stated on the hard copi[INVESTIGATOR_227519] b y the 
investigator. 
If the ECG trace indicates an abnormalit y that is measured by [CONTACT_227557] b y the investigator, then this should be clearl y stated on the 
ECG tracing as normal and signed and dated b y the investigator or appropriately  
qualified designee.  If the ECG tracing indicates an abnormality  that is p resent 
but deemed as not clinically  significant b y the investigator or appropriately 
qualified designee, then this should be clearl y stated on the ECG tracing as 
“NCS” and signed and dated b y the investigator or appropriately qualified 
designee and stored with the source records for that participant.  If an y results 
falling outside of the normal ranges are deemed clinically  significant b y the 
investigator or appropriately  qualified designee then these should be recorded in 
the eCRF as an AE. 
ECGs will be s tored electronically  for manual measurement of intervals, if 
necessary . 
Whenever a 12 -lead ECG is scheduled at the same nominal time as other study  
procedures (including vital signs, blood draws, or meals), the ECG should be 
obtained first followed by [CONTACT_227558].
8.2.4. Telemetry
Telemetry  will be performed during the stud y as outlined in the SoA. Additional details 
are available in the SRM.
8.2.5. Holter Monitoring
Cardiac monitoring (24 hour) will be performed using continuous Holter monitoring 
during the stud y as shown in the SoA. 
Start date and time andstop date and time will be captured in the study  database.  
Analy sis of the Holter monitoring will consider the following:
Heart rate (HR)(brad y and tachy cardia).
Normal and aberrant beats.
Number of supraventricular contractions, premature atrial contractions, 
supraventricular tach ycardias, premature ventricular contractions, couplets, 
triplets and ventricular tachy cardias.
Atrio -ventr icular conduction defects.
2018N361438_05 CONFIDENTIA L
209275
84Atrial fibrillation and flutter.
8.2.6. Clinical Safety  Laboratory  Assessments
Refer to Appendix 2forthe list of clinical laboratory  tests to be performed and 
to the SoA for the timing and frequen cy. 
The investigator must review the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the CRF. The laboratory  reports must be filed with the source 
documents. Clinically  significant abnormal laboratory  findings are those which 
are not associated with the underl ying disease, unless judged b y the investigator 
to be more severe than expected for the participant's condition.
All laboratory  tests with values considered clinicall y significantl y abnormal 
during participation in the study  or within [ADDRESS_274153] dose of study  
intervention should be repeated until the values return to normal or B aseline or 
are no longer considered significantl y abnormal by [CONTACT_093] o r medical 
monitor. Any lab or clinical assessment that is judged to be spurious by  [CONTACT_227559] I nvestigator ( PI)may be repeated.
If such valu es do not return to normal/B aseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the SoA.
Samples collected for hematology , clinical chemistry , urinaly sis, or hormone 
assay s will be anal ysed at the unit’s local laboratory  under the relevant Standard 
Operating Procedures ( SOPs ), GUIs and user manuals.  See user local laboratory  
manuals for details on methodology , processing, handling of specimens , and 
analyses.
Hematology , clinical chemistry , urinal ysis and additional parameters to be tested 
are listed in Appendix 2.
8.2.7. Hormone Monitoring
Based on preclinical findings in the rat Good Laboratory  Practice ( GLP )toxicology 
studies outlined in the IB , hormone monitoring will take place in Part B of the study  only. 
Blood samples will be obtained as per the SoA and SRM and analy sed for: 
Adrenal –ACTH, cortisol
Pi[INVESTIGATOR_2117]  –LH, FSH, TSH , T3, and free T4 
Total Testoster one and DHT
All laboratory  tests with values that are considered clinically  significantl y abnormal
during participation in the study  or until the final follow up visit should be repeated until
the values return to normal or Baseline or are no longer consi dered significantly  
abnormal by [CONTACT_10982]. If such values do not return to normal 
2018N361438_05 CONFIDENTIA L
209275
85within a period judged reasonable b y the investigator, the etiology should be identified 
and the sponsor notified.
8.2.8. Suicidal Ideation and Behaviour R isk Monitoring
Not applicable.
8.3. Adverse Events and Serious A dverse Events
The definitions of an AE or SAE can be found in Appendix 3 .
The investigator and an y qualified designees are responsible for detecting, documenti ng, 
and reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AE sthat are serious, considered related to the study  intervention or the 
study , or that caused the participant to discontinue the study  intervention (see Section 7). 
8.3.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAE swill be collected from the start of intervention until the follow -up visit
at the time points specified in the SoA (Sect ion 1.3).However, an y SAEs 
assessed as related to study  participation (e.g., study  intervention , protocol -
mandated procedures, invasive tests, or change in existing therapy ) or related to 
a [COMPANY_004] product will be recorded from the time a participant consents to 
participate in the stud y.
All AE swill be collected from the start of intervention until the follow -up visit
at the time points specified in the SoA (Section 1.3).
Medical occurrences that begin before the start of study  intervention but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the CRF not the AE section.
All SAE swill be recorded and reported t o the sponsor or designee immediately  
and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3 . The investigator will submit any  updated SAE data to the sponsor 
within 24 hours of it being avai lable.
Investigators are not obligated to activel y seek AEs or SAEs after the conclusion 
of the study  particip ation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has been discharged from the 
study , and he/she considers the event to be reasonably  related to the study  
intervention or study  participation, the investigator must promptly  notify  the 
sponsor.
8.3.2. Method of Detecting A Es and SA Es
The method of recording, evaluating, and assessing causality  of AEs an d SAEs 
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 3 .
2018N361438_05 CONFIDENTIA L
209275
86Care will be taken not to introduce bias when detecting AE and/or SAE. Open -
ended and non -leading verbal questioning of the participant is the preferred 
method to inquire about AE occurrence. 
8.3.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs will be followed until the event is 
resolved, stabilized, otherwise explained, or the participant is lost to follow -up (as 
defined in Section 7.3). Further information on follow -up procedures is given in 
Appendix 3 .
8.3.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of 
participants and the safety  of a study  intervention under clinical investigation are 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y intervention
under clinical investigation. The sponsor will comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
Institutional Review Boards (IRB)/Independent Ethics Committees (I EC), and 
investigators.
Investigator safety  reports must be prepared for suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) according to local regulatory  requirements and 
sponsor policy  and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE or 
other specific safet y information (e.g., summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements.
8.3.5. Pregnancy
Details of all pregnancies in f emale partners of male participants will be collected 
after the start of stud y intervention and until follow -up.
If a pregnancy  is reported, the investigator should inform [COMPANY_004] within 24 hours of 
learning of the pregnancy  and should follow the procedures ou tlined in Appendix 4.
Abnormal pregnancy  outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
8.4. Treatment of Overdose
For this study , any  dose of [COMPANY_004] 3439171A greater than 3000 mg within a 24 -hour time 
period (1 hour) will be considered an overdose.
2018N361438_05 CONFIDENTIA L
209275
87Sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_227560] y.
2.Closely  monitor the participant for AE/SAE and laboratory  abnormalities until 
[COMPANY_004]3439171A can no longer be detected s ystemically  (at least 5 days).
3.Obtain a plasma sample for PK anal ysis if requested by  [CONTACT_1689] 
(determined on a case -by-case basis).
4.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the CRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_227561] e valuation of the 
participant.
8.5. Pharmacokinetics
8.5.1. Blood Sample Collection
Whole blood samples of approximately  2mL will be collected for measurement 
of plasma concentrations of [COMPANY_004]3439171A as specified in the SoA .The timing 
of PK samples may  be altered and/ or PK samples may  be obtained at additional 
time points to ensure thorough PK monitoring . Instructions for the collection and 
handling of biological samples will be provided by  [CONTACT_456]. The actual date 
and time (24 -hour clock time) of each sample will be recorded.
In Part B, at each sampling time point an additional 2 mL blood will be collected 
for metabolite profiling. Results will be reported under a separate PTS-Global 
Spectroscop y, [COMPANY_004] protocol.
Samples will be used to evaluate the PK of [COMPANY_004]3439171A . Samples collected for 
analyses of stud y intervention plasma concentration may  also be used to evaluate 
safet y or efficacy aspects related to concerns arising during or after the study.
Genetic analyses will not be performed on these whole blood samples [unless 
consent for this was included in the informed consent]. Participant confidentiality  
will be maintained. 
Details of blood sample processing, storage and shippi[INVESTIGATOR_227520] .
8.5.2. Urine Sample Collection
In Part B on ly, urine samples will be collected as outlined in the SoA and urine PK 
calculations of [COMPANY_004]3439171A (including renal clearance) , will be performed, as 
appropriate. These samples may  also be anal ysed for additional metabolites of 
[COMPANY_004]3439171A as appropriate. The timing of urine samples may  be altered and/or 
samples may  be obtained at additional time points to ensure thorough PK monitoring.
2018N361438_05 CONFIDENTIA L
[ADDRESS_274154] dose cohort in Part B
(depending on PK results in Part A) as outlined in the SoA .  The Entero -Test is a gelatin 
capsule containing a weighted n ylon line.  The Entero -Test will be swallowed 
approximately  [ADDRESS_274155] bile sample collected from placebo -dosed subjects will be considered as the 
control.
Additional d etails of the bile sample collection procedure , processing, storage and 
shippi[INVESTIGATOR_227521] .
8.5.4. Sample A nalysis
Plasma ,urine , and muscle (as appropriate) analysis will be performed under the control 
of PTS Bioanal ysis, US, G laxoSmithKline, the details of which will be included in the 
SRM .  Concentrations of [COMPANY_004]3439171A will be determined in plasma ,urine , and muscle
samples using the currently  approved bioanal ytical methodology .  Raw data will be 
archived at the bioanal yticalsite (detailed in the SRM) or equivalent .
Plasma , bile and urine samples may  be anal yzed for other compound -related metabolites 
and the results reported under a separate PTS Global Spectroscop y, GlaxoSmithKline 
protocol .
Drug concentration information tha t may  unblind the study  will not be reported to 
investigative sites or blinded personnel until the study  has been unblinded .
8.6. Pharmacody namics
Under guidance of the SRM or equivalent , samples will be shipped to GlaxoSmithKline
or appropriate third -party ven dors for anal ysis. 
2018N361438_05 CONFIDENTIA L
209275
898.6.1. Urine Pharmacody namics A ssessment
Subaliquot sof the urine samples collected in Parts A and B will be designated for 
measurement of prostaglandin and/or inflammatory PD markers, including but not 
limited to tPGDM and tPGEM, at the time points outlined in the SoAs in Section 1. See 
SRM (or equivalent) for details on sample collection, processing, and storage.
8.6.2. Muscle Biopsy
Muscle biopsies will be obtained in order to examine PK/PD of [COMPANY_004]3439171 A as well as 
H-PGDS inhibition in a tissue of potential relevance. Information gained from these 
biopsies will also help in determining dose selection for future studies. Under local 
anesthesia, skeletal muscle biopsies will be obtained from the vastus lateralis at the time 
points indicated in Part B of the SoA. See SRM or equivalent for details on the 
procedure, sample collection, and storage.
8.7. Genetics
A 6mL blood sample for deox yribonucleic acid ( DNA )isolation will be collected from 
participants who hav e consented to participate in the genetics anal ysis component of the 
study . Participation is optional. Participants who do not wish to participate in the genetic 
research may  still participate in the study .
In the event of DNA extraction failure, a replace ment genetic blood sample may  be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.
See Appendix 5for informa tion re garding genetic research . Details on processes for 
collection and shipment and destruction of these samples can be found in the SRM or 
equivalent .
8.8. Biomarkers
Collection of samples for other biomarker research is also part of this study .Refer to the 
SoA an d SRM (or equivalent )for details on timings.
These samples may  be used for research to develop methods, assay s, prognostics and/or 
companion diagnostics related to prostaglandin and/or inflammatory -mediate ddisease s.
Samples may  be stored for a maximum of 15years (or according to local regulations) 
following the last participant’s last visit for the study  at a facility  selected by  [CONTACT_227562]3439171A . 
8.9. Health Economics orMedical Resource Utilizatio n and 
Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are 
not evaluated in this study .
2018N361438_05 CONFIDENTIA L
209275
909. STATISTICA L CONSIDER ATIONS
9.1. Statistical Hy potheses
The primary  objectives of this study  are to evaluate safet y and tolerabi lity of single and 
repeat doses of [COMPANY_004]3439171A and to characterize the PK of [COMPANY_004]3439171A. No formal 
statistical hy potheses will be tested.  Descriptive statistics will be used to assess safet y 
and tolerability  objectives.  Treatment comparisons with placeb o will be based on review 
of descriptive statistics and individual participant data.  An estimation approach will be 
used to address the PK objectives where point estimates and corresponding 90% 
confidence intervals ( CIs)will be constructed as appropriate for the assessment of dose -
proportionality , stead y-state, time invariance and food effect.
Estimation of effects of [COMPANY_004]3439171A on PD/biomarkers is an exploratory objective.  
No formal statistical h ypotheses will be tested.  An estimation approach will be used to 
address these objectives, where point estimates and corresponding CIs will be constructed 
as appropriate.
Unblinded, in -stream data reviews will be performed for Parts A and B in order to inform 
dose-escalation decisions. Final results for each st udy part (A, B, C) may  be reported as 
each part completes rather than after completion of all study  parts.
9.2. Sample Size Determination
The sample size for the study  is not based on statistical considerations.  The sample size 
for Part A (single dose, dose -escalation) has been selected to provide sufficient safet y, 
tolerability  and PK data to support escalation to the next single dose level in Part A and 
to support selection of dose levels for Part B while minimizing the number of participants 
exposed to study drug.  Similarly , the sample size for Part B (repeat dose, dose -
escalation) has been selected to provide sufficient safet y, tolerabilit y and PK data to 
support escalation to the next repeat dose level in Part B and to support dose selection for 
subsequent studies.
The sample size for Part C (food effect) was selected in the absence of estimates of 
variability  for PK parameters as the minimum needed to adequately  estimate food effect 
and may  be re -estimated based on the observed PK variability  from Part A.
Approximately  150 participants will be screened to achieve 75 randoml y assigned to 
study  intervention and 75 evaluable participants for an estimated total of 27 evaluable 
participants in Part A (6 active: 3 placebo per cohort), 36 evaluable participants in Part B 
(9 active:3 placebo per cohort), and 12 evaluable participants in Part C. 
9.3. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
2018N361438_05 CONFIDENTIA L
[ADDRESS_274156]-Baseline PD measure.
9.4. Statistical A nalyses
Pharmacokinetic Analyses
PK analy sis will be the responsibility  of the Clinical Pharmacology  Modeling and 
Simulation Department, CPMS, GlaxoSmithKline. Plasma [COMPANY_004]3439171A concentration -
time data will be analyzed by  [CONTACT_105]-compartmental methods with WinNonlin 5.2 or higher.  
Calculations will be based on the actual sampling times recorded during the study .  
From the plasma concentration -time data, the following PK parameters will be 
determined, as data permi t: 
Apparent Clearance (CL/F)
maximum observed blood concentration (Cmax), 
time to Cmax (tmax), 
area under the plasma concentration -time curve [AUC(0-t), AUC(0 -inf) and 
AUC(0 -τ)]
apparent terminal phase half -life (t 1/2)
trough concentration (C ).  
AUC(0 -∞) or AUC(0 -τ) and Cmax following single and repeat doses may  be used for 
assessment of dose proportionality .  Trough concentration (C ) samples collected on the 
specified day s will be used to assess attainment of steady  state and the steady  state ratio 
2018N361438_05 CONFIDENTIA L
209275
92(Rss) will be calculated (Day  16AUC(0 -τ)/Day  1 AUC(0 -inf)). To estimate the extent of 
accumulation after repeat dosing, the observed accumulation ratio (Ro: Day 13 or17
AUC(0 -)/Day  1 AUC(0 -); and RCmax: Day  13 or 17Cmax/Day  1 Cmax)  will be 
determined.
PK data will be presented in graphical and/or tabular form and will be summarized 
descriptivel y.
Statistical analy ses of the PK parameter data will be the responsib ility of Clinical 
Statistics, GlaxoSmithKline. Distributional assumptions underly ing the statistical 
analyses will be assessed by  [CONTACT_227563]. Normality  will be 
examined by  [CONTACT_227564], while homogeneity  of variance wil l be assessed b y 
plotting the residuals against the predicted values for the model. If there are an y 
important departures from the distributional assumptions, alternative models may  be 
explored using appropriately  transformed data. Full details on the stat istical aspects will 
be described in the Reporting and Analy sis Plan (RAP).
Dose Proportionality (Parts A and B: Single and Repeat Dose Study Phases)
Dose proportionality  will be assessed following single doses of [COMPANY_004] 3439171 A (Part A) 
via anal yses of AUC( 0-t), AUC(0 -inf), and Cmax. Dose proportionality  following 
repeated dosing (Part B) will be assessed using AUC(0 -τ) and Cmax.
A statistical anal ysis will be performed for each parameter separatel y using the power 
model with the log -transformed PK parameter as the dependent variable and log(dose) as 
a fixed effect. For Part A, the intercept and slope will be fit as random effects.  I n 
addition, effects for cohort and cohort b y log(dose) may be included in the model to 
examine differences in slopes across coho rts. Estimates of the slopes will be reported 
along with corresponding 90% CIs(slope≈1 implies dose proportionalit y).
Food Effect (Part C: Single Dose Study)
The effect of food on the PK of [COMPANY_004] 3439171 A(AUC(0 -inf), Cmax, and t1/2) will be 
examined. An analysis of variance model will be fitted separatel y to each of the log-
transformed PKparameters with period and treatment (fed or fasted) as fixed effects and 
participant as a random effect. Point estimates for the differences in means 
([COMPANY_004] 3439171 Afed –[COMPANY_004] 3439171 Afasted) and corresponding 90% CIs will be 
constructed from the least squares means, using the residual variance. These will then be 
back -transformed to provide point estimates and corresponding 90% CIsfor the ratio of 
geometric means fed:fasted.
Accumulation (Part B: Repeat Dose Study Phase)
The extent of accumulation of [COMPANY_004] 3439171 Awill be based on AUC (Ro) and Cmax 
(RCmax). 
Statistical analy sis of log-transformed AUC(0 -) and Cmax will be performed separatel y 
and by [CONTACT_227565] a fixed, categorical effect for day and a 
random effect for participant. The accumulation ratios (Ro and RCmax) of 
2018N361438_05 CONFIDENTIA L
[ADDRESS_274157] 
squares means (Day  13 or 17–Day 1) and the associated 90% CI. 
Time Invariance
Assessment of the achievement of steady  state will be based on the AUC (Rss).  The time 
invariance ratio will be calculated as the ratio of AUC(0 -) on Day  13 or 17over AUC(0 -
inf) on Day 1. The time invariance ratio will be listed and summarized along with other 
PK parameters. 
Statistical analy sis of the log-transformed AUCs will be performed separatel y for each 
dose using an ANOVA model with a fixed, categorical effect for day  and a random effect 
for participant. The time invariance ratio of [COMPANY_004] [ADDRESS_274158] squares means (Day  17–Day 1) and the 
associated 90% CI. The values of AUC used in the analy sis will be AUC(0 -inf) on Day  1 
and AUC(0 -) on Day  13 or 17.
Achievement of Steady State (Part B: Repeat Dose Study Phase)
Steady -state will be assessed visually  by [CONTACT_227566], Cτ, 
collected pre -morning dose versus collection day  by [CONTACT_2715].  I n addition, statistical anal ysis 
of trough concentration levels ( e.g.,Days6,7,9, and 10 (7 day repeat dosing period) or 6-
7,16-17(14 day repeat dosing period ) will be performed after log-transformation of the 
concentrations. A mixed effects ANOVA model will be fit with day  (continuous variable) 
as a fixed effect and subject as a random effect for each dose level separatel y.  The 
coefficient for the slope of the day effect on the log-scale will be used to evaluate steady  
state for each dose.  The 90% confidence intervals for the slope will be calculated .
2018N361438_05 CONFIDENTIA L
209275
949.4.1. Safety  Analyses
All safet y anal yses will be performed on the Safety  Population. 
Endpoint Statistical Analysis Methods
Primary Descriptive s tatistics will be used to assess safety and tolerability objectives.  No 
formal statistical analyses of safety data are planned. Data will be summarized 
according to [COMPANY_004] Integrated Data Standards Library (IDSL) standards. In 
addition, individual participan t data will be reviewed. Treatment comparisons with 
placebo will be based on review of descriptive statistics and individual participant 
data.
9.4.2. Other A nalyses
In Parts A and B, dose -response modelling of urinary  tPGDM/tPGEM will be 
undertaken, data permit ting. Details will be described in the reporting and anal ysis plan.
The population PK anal ysis a nd pharmacod ynamic anal yses may be presented separatel y 
from the main clinical study  report (CSR). 
9.5. Interim Analyses
There will be no formal statistical interim analy sis.  However, preliminary  safet y, PK, 
and PD/biomarker data will be reviewed in -stream by  [CONTACT_227567].  Data for these reviews will be cumulative and can include 
individual participant data, summaries b y treatment group and graphical display s.  This is 
a sponsor unblinded trial and [COMPANY_004] staff will be unblinded for these reviews (see Section 
6.3).
Preliminary  results from available safet y data may be reported prior to database fr eeze for 
the purposes of safet y review by [CONTACT_23983], and where required b y regulatory  bodies.
Other selected preliminary data may  be unblinded and reported prior to database freeze 
for internal decision making. 
In each case described above, the study  will not b e officiall y unblinded and access to the 
randomization will be restricted.
9.5.1. Data Monitoring Committee (DMC)
Dose modifications, including dose escalations, will be reviewed b y the dose escalation 
committee. This committee includes, but is not limited to , the medical monitor, principal 
investigator, clinical scientists, safety  physician and/or representative, and clinical 
pharmacokineticist .Dose escalation decisio ns will be made as outlined in Section 4.1and 
Section 6.6and in the Dose Escalation Plan.
2018N361438_05 CONFIDENTIA L
[PHONE_4809]. SUPPORTING DOCUMENTA TION AND OPERA TIONAL
CONSIDERA TIONS
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight 
Considerations
10.1.1. Regulatory  and Ethical Considerations
This st udy will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International E thical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents ( e.g., advertisements) must be submitted to an I RB/IEC by  
[CONTACT_20003] b y the I RB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an im mediate hazard to study  participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and procedures e stablished by  [CONTACT_1201]/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, E uropean 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
10.1.2. Financial Disclosure
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to a llow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and f or 1 y earafter completion of the study .
2018N361438_05 CONFIDENTIA L
[PHONE_4810].1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to 
the participant or his/her legally  authorized representative and answer all 
questions regarding the study . 
Participants must be informed that their participation is voluntary . Participants 
or their legall y authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_274159] (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study . 
A co py of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreened are required to sign a new ICF.
The I CF may  contain a separate section that addresses the use of remaining mandato ry 
samples for optional exploratory  research in accordance with SOP -[COMPANY_004]F -410. The 
investigator or authorized designee will explain to each participant the objectives of the 
exploratory  research. Participants will be told that they  are free to refuse to par ticipate 
and may  withdraw their consent at any  time and for an y reason during the storage period. 
A separate signature [CONTACT_22862] a participant's agreement to allow any  
remaining specimens to be used for exploratory  research. Participants who decline to 
participate will not p rovide this separate signature.
10.1.4. Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  [CONTACT_227568] w. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appointed 
by [CONTACT_456], b y appropria te IRB/IEC members, and by  [CONTACT_43216].
2018N361438_05 CONFIDENTIA L
209275
97Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
thesponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generall y support publication of multicenter studies only in their entiret y and not 
as individual site data. In this case, a coordinating investigator [INVESTIGATOR_43192] b y mutual agreement.
Authorship will be determined by  [CONTACT_11402] a nd in line with 
International Committee of Medical Journal Editors authorship requirements.
10.1.5. Dissemination of Clinical Study  Data
Where required b y applicable regulatory  requirements, an investigator signatory  
will be identified for the approval of the clin ical study  report.  The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity  to review the complete study  results at a 
[COMPANY_004] site or other mutually -agreeable location.
[COMPANY_004] will als o provide the investigator with the full summary  of the stud y 
results.  The investigator is encouraged to share the summary  results with the 
study  subjects, as appropriate.
[COMPANY_004] will provide the investigator with the randomization codes for their site 
only after completion of the full statistical anal ysis.
The procedures and timing for public disclosure of the protocol and results 
summary  and for development of a manuscript for publication for this study  will 
be in accordance with [COMPANY_004] Policy .
[COMPANY_004] intends to make anony mized patient -level data from this trial available to 
external researchers for scientific anal yses or to conduct further research that 
can help advance medical science or improve patient care. This helps ensure the 
data provided b y trial particip ants are used to maximum effect in the creation of 
knowledge and understanding
A manuscript will be progressed for publication in the scientific literature if the 
results provide important scientific or medical knowledge.
10.1.6. Data Quality  Assurance
All partic ipant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (e.g., 
laboratory  data). The investigator is responsible for verify ing that data entries 
are accurate and correct by [CONTACT_227569]. 
2018N361438_05 CONFIDENTIA L
209275
98The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regula tory agency  inspections and provide direct access to source data 
documents. 
Monitoring details describing strategy  (e.g., risk -based initiatives in operations 
and quality  such as Risk Management and Mitigation Strategies and Anal ytical 
Risk-Based Monitori ng), methods, responsibilities and requirements, including 
handling of noncompliance issues and monitoring techniques (central, remote, 
or on -site monitoring) are provided in the Monitoring Plan .
The sponsor or designee is responsible for the data manageme nt of this study  
including qualit y checking of the data. 
The sponsor assumes accountability  for actions delegated to other individuals 
(e.g., Contract Research Organizations).
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of participants 
are being protected; and that the study  is being conducted in accordance with the 
currentl y approv ed protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this 
study  must be retained by  [CONTACT_1732] 25 y ears from the issue of the f inal 
Clinical Study  Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may  be 
destroy ed during the retention period without the written approval of the 
sponsor. No records may b e transferred to another location or part y without 
written notification to the sponsor. 
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are file d at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may  need to request previous 
medi cal records or transfer records, depending on the study . Also, current 
medical records must be available.
Definition of what constitutes source data can be found in Source Document 
Agreement .
2018N361438_05 CONFIDENTIA L
[PHONE_4811].1.8. Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected an d a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitme nt of participants by  [CONTACT_093]
Discontinuation of further study  intervention development
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all m anuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. 
In accordance with standard edito rial and ethical practice, the sponsor will 
generall y support publication of multicenter studies only in their entiret y and not 
as individual site data. In this case, a coordinating investigator [INVESTIGATOR_43192] b y mutual agreement.
Authorship will be de termined by  [CONTACT_43217].
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE].2. Appendix 2: Clinical Laboratory  Tests
The tests detailed in Table 3will be performed by [CONTACT_12082] . 
Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5of the protocol.
Additional tests may  be performed at an y time during the stud y as determi ned 
necessary  by [CONTACT_43215].
Pregnancy  Testing 
Refer to Section 5.1Inclusion Criteria for screening pregnancy  criteria.
Table 3 Protocol -Required Safety  Laborato ry Assessments
Hematology
Platelet Count RBC Indices : Automated WBC Differential :
RBC Count MCV Neutrophils
WBC Count (absolute) MCH Lymphocytes
Reticulocyte Count MCHC Monocytes
Hemoglobin Prothrombin time (with and without INR) Eosinophils
Hemato crit Activated partial thromboplastin time Basophils
Clinical Chemistry
BUN Potassium AST (SGOT) Total and direct bilirubin
Creatinine Chloride ALT (SGPT) Uric Acid
Glucose Total CO 2 GGT Albumin
Sodium Calcium Alkaline phosphatase Total Protein
Creatine Phosphokinase (Total)
Hormone A ssessments
Luteinizing hormone 
(LH)Total Testosterone Adrenocorticotropic 
hormone (ACTHcortisol Free T4
Follicle stimulating 
hormone (FSH)Dihydrotestosterone 
(DHT)Thyroid stimulating 
hormone (TSH)T3
Routin e Urinalysis
Specific gravity
pH, glucose, protein, blood and ketones by [CONTACT_19508] (if blood or protein is abnormal)
2018N361438_05 CONFIDENTIA L
209275
101Other screening tests
HIV
Hepatitis B (HBsAg)
Hepatitis C (Hep C antibody --if second generation Hepatitis C antibody positive, a hepatitis C antibody 
Chiron RIBA immunoblot assay (or other third generation immunoassay) should be reflexively performed on 
the same sample to confirm the result) 
Cotinine, Serum Alcohol, and drug screen (to include at minimum: am phetamines, barbiturates, cocaine, 
opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651]).
NOTES :
1.Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver 
stoppi[INVESTIGATOR_31777] 7.1and Appendix 7All events of ALT 3 × upper 
limit of normal (ULN) and bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and 
international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury 
(possible Hy’s Law ), must be reported as an SAE (excluding studies of hepatic impairment or 
cirrhosis).
[ADDRESS_274160] for the protocol unless serum testing is required by [CONTACT_227570]/IEC.
Local urine testing will be standard for the protocol unless serum testing is required b y 
local regulation or IRB/IEC.
Laboratory /anal yte results that could unblind the study  will not be reported to 
investigative sites or other blinded p ersonnel unt il the study  has been unblinded .
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE].3. Appendix 3: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant , temporally  
associated with the use of a study  intervention, whether or not considered related to 
the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments ( e.g., ECG, radiological scans , vital signs 
measurements), in cluding those that worsen from B aseline, considered clinically  
significant in the medical and scientific judgment of the investigator ( i.e., not related 
to progression of underl ying disease).
Exacerbation of a chronic or inte rmittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unle ss it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Suc h instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy  will be reported as AE or SAE if they  fulfill the definition of an AE 
or SAE. 
The signs, s ymptoms, and/or clin ical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfill the definition of an AE or SAE. Also, "lack of 
efficacy " or "failure of expected pharmacological action" constitutes an AE or SAE.
Events NOT Meeting the AE Defini tion 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
2018N361438_05 CONFIDENTIA L
209275
103assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The dis ease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure ( e.g., endoscopy , appendectom y): the condition th at 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.3.2. Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to pr ogression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
oResults in death
oIs life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_91260] p articipant has been detained (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur du ring hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_227522] a pre -existing cond ition that did not worsen from 
Baseline is not considered an AE.
Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life f unctions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
2018N361438_05 CONFIDENTIA L
209275
104and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
Is a congenital anomaly/birth defect
Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may  
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_227523]. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hosp italization, or development of drug dependency 
or drug abuse.
10.3.3. Recording and Follow -Up of A E and S AE
AE and SAE Recording
 When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laborat ory, and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completio n of the [COMPANY_004] /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_227524].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented a s the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
2018N361438_05 CONFIDENTIA L
209275
105 Severe: An event that prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in t he definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
 The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s) , concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occur red and the investigator has 
minimal information to include in the initial report to [COMPANY_004]. However , it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004].
Theinvestigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requi rements.
Follow -up of AE and SAE
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_31859]/or causalit y of the AE or SAE as fully  as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follo w-
up period, the investigator will provide [COMPANY_004] with a cop y of an y post-mortem 
2018N361438_05 CONFIDENTIA L
209275
106findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within 2 4 hours of 
receipt of the information.
10.3.4. Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Collection Tool
 The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.
If the electronic s ystem is unavailable, t hen the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
The investigator or medically -qualified s ub-investigator must show evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to I P/study  participation (causalit y) within 72 hours of SAE 
entry  into the eCRF.
After the stud y is com pleted at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  repo rted SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the medical monitor by [CONTACT_756].
Contacts fo r SAE reporting can be found in Study Reference Manual .
SAE Reporting to [COMPANY_004] via Paper CRF
 Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the medica l monitor .
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_97535] e is acceptable with a cop y of the SAE data collection tool sent by [CONTACT_19515].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in the Study  Reference Manual .
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE].4. Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy  Information
10.4.1. Contraception Guidance:
CONTRACEPTIVES aALLOWED FOR FEMALE PARTNERS OF PARTICIPANTS DURING 
THE S TUDY INCLUDE:
 Highly Effective Methods bThat Have Low User Dependency 
 Implantable progestogen -only hormone contraception associated with inhibition of ovulation c
 Intrauterine device (IUD)
 Intrauterine hormone -releasing system (IUS) c
 Bilateral tubal o cclusion
 Vasectomized partner
Note: Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the absence 
of sperm has been confirmed. If not, an additio nal highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90 days.
 Highly Effective Methods bThat Are User Dependent
 Combined (estrogen -and progestogen -containing) hormonal contraception associated with 
inhibiti on of ovulation c
oral
intravaginal
transdermal
injectable
 Progestogen -only hormone contraception associated with inhibition of ovulation c
oral
injectable
 Sexual abstinence
Note :Sexual abstinence is considered a highly effective method only if defined as
refraining from heterosexual intercourse during the entire period of risk associated with 
the study intervention. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the participant
a.Contraceptive use by [CONTACT_103092].
b. Failure rate of <1%  per year when used consistently and correctly. Typi[INVESTIGATOR_19529] l use failure rates differ from those when 
used consistently and correctly.
c. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive 
methods are limited to those which inhibit ovulation as the pr imary mode of action.
Note: Periodic abstinence (calendar, sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception for this 
study. Male condom and female condom should not be used together (due to risk of failure with friction)
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE].4.2. Collection of Pregnancy  Information:
Male participants with partners who become pregnant
Investigator will attempt to collect pregnancy  information on any  male p articipant’s 
female partner of a male study  participant who becomes pregnant while participating 
in this study . This applies only  to male participants who receive [COMPANY_004]3439171A .
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the investigator will record pregnancy information on the 
appropriate form and submit it to [COMPANY_004] within 24 hours of learning of the partner’s 
pregnancy . 
The female partner will also be followed to determine the outcome of the pregnancy . 
Information on the status of the mother and child will be forwarded to [COMPANY_004].
Generally , follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date. An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure. 
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE].5. Appendix 5: Genetics
USE/ANALYSIS OF DNA
Genetic variation may  impact a participant’s response to study  intervention , 
susceptibility , severit y and progression of disease. Variable response to study  
intervention may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion; mechanism of action of the drug; disease 
etiology ; and/or molecular subty pe of the disease being treated. Therefore, where 
local regulations and IRB/IEC allow, a blood sample will be collected for DNA 
analysis
DNA samples will be used for research related to [COMPANY_004]3439171A or prostaglandin or 
inflammation -mediated disease . They  may  also be used to develop tests/assay s 
including diagnostic tests) related to [COMPANY_004]3439171A or study  interventions of this 
drug class and prostaglandin or inflammation -mediated disease . Genetic research 
may consist of the anal ysis of one or more candidate genes or the anal ysis of genetic 
markers throughout the genome or ana lysis of the entire genome (as appropriate)
DNA samples will be analy zed if it is hy pothesized that this may  help further 
understand the clinical data. 
The samples may  be analy zed as part of a multi -study  assessment of genetic factors 
involved in the resp onse to [COMPANY_004]3439171A or study  interventions of this class. The 
results of genetic anal yses may  be reported in the clinical study  report or in a 
separate study  summary .
The sponsor will store the DNA samples in a secure storage space with adequate 
measures t o protect confidentiality . 
The samples will be retained while research on [COMPANY_004]3439171A (or study  
interventions of this class) or prostaglandin or inflammation -mediated disease
continues but no longer than [ADDRESS_274161] visit or other period as 
per local requirements.
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE].6. Appendix 6: Liver Safety : Required A ctions and Follow -up 
Assessments
Phase I liver chemistry stoppi[INVESTIGATOR_227525]-absoluteALT≥3xULN
If ALT ≥3xULN AND bilirubin 1,22xULN (>35% direct bilirubin) or INR>1.5, 
Report as an SAE.
See additional Actions and Follow Up Assessments listed below
Required Actions and Follow up Assessments 
Actions Follow Up Assessments
Immediately discontinue study intervention
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF, and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE 2
Perform liver event follow up assessments 
Monitor the subject unti l liver chemistries 
resolve, stabilise, or return to within B aseline 
(see MONITORING below)
MONITORING:
If ALT ≥3xULN AND bilirubin 2xULN or INR 
>1.5
Repeat liver chemistries (include ALT, 
aspartate transaminase [AST ], alkaline 
phosphatase, bilirubin and INR) and perform 
liver event follow up assessments within 24 
hrs
Monitor subjects twice weekly until liv er 
chemistries resolve, stabilise or return to 
within B aseline
A specialist or hepatology consultation is 
recommended
If ALT ≥3xULN AND bilirubin < 2xULN and INR 
≤1.5:
Repeat liver chemistries (include ALT, AST, Viral hepatitis serology 3
Obtain international normalized ratio (INR) 
and recheck with each liver che mistry 
assessment until the transaminases values 
show downward trend
Obtain blood sample for pharmacokinetic 
(PK) analysis, obtained within [ADDRESS_274162] dose 4 
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the conc omitant medications report form 
including acetaminophen, herbal remedies, 
other over the counter medications.
Record alcohol use on the liver event 
alcohol intake case report form
If ALT ≥3xULN AND bilirubin 2xULN or INR 
>1.5:
Anti-nuclear antibody, anti -smooth muscle 
2018N361438_05 CONFIDENTIA L
209275
111alkaline phosphatase, bilirubin and INR) and 
perform liver event follow up assessments 
within 24-72 hrs
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within B aselineantibody, Type 1 anti -liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins.
Serum acetaminophen adduct high 
performanc e liquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophen contribution to liver injury 
in subjects with definite or likely 
acetaminophen use in the preceding week 
[James , 2009]. NOTE: not required in 
China.
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1.Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study intervention for that subject if ALT 3xULN and bilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urina ry bilirubin on 
dipstick, indicating direct bilirubin elevations and suggesting liver injury. 
2.All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, which 
may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding studies of hepatic 
impairment or cirrhosis); the threshold value stated will not apply to subjects receiving anticoagulants
3.Includes: Hepatitis A immunoglobulin (gM) antibody; HBsAg and HBcAb; Hepatitis C RNA; Cytomeg alovirus IgM 
antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain heterophile antibody or 
monospot testing) and Hepatitis E IgM antibody 
4.PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] co mparator interventions.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study intervention prior to 
PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approxi mation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971] .
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE].7. Appendix 7: Abbreviations an d Trademarks
Abbreviations
µg microgram
ACTH Adrenocorticotropic Hormone
AE adverse event
ALKP Alkaline Phosphatase
ALT Alanine Transferase
ANOVA Analy sis of Variance
AST Aspartate Aminotransferase
AUC Area Under the Curve
BID Twice Dail y
BMI Body Mass Index
BP Blood Pressure
BUN Blood Urea Nitrogen
CIOMS Council for International Organizations of Medical Sciences
Cmax Maximum Concentration
CO2 Carbon Dioxide
CONSORT Consolidated Standards of Report Trials
COX Cycloox ygenase
CPMS Clinical Pharmacology  Modelling and Simulation
CRF Case Report Form
CSR Clinical Study  Report
CTCAE Common Terminology  Criteria for Adverse Events
CTFF Clinical Trial Facilitation Group
Cτ Trough Concentration
CV Cardiovascular
D Dose
DHT Dihy drotestosteron e
DMPK Drug Metabolism and Pharmacokinetics
DNA Deox yribonucleic Acid
ECG Electrocardiogram
ED50 Median Effective Dose
Emax Maximum Efficacy
FDA Food and Drug Administration
FSH Follicle -stimulating Hormone
FTIH First Time In Human
g Gram
GCP Good Clinical Practice
GCSP Global Clinical Safety  and Pharmacovigilance
GGT Gamma -glutam yl Transferase
GLDH Glutamate Deh ydrogenase
2018N361438_05 CONFIDENTIA L
[ADDRESS_274163]
HIV Human Immunodeficiency  Virus
H-PGDS Hematopoietic Prostaglandin D2 Sy nthase
hr hours
hr-1Per hour
HR Heart Rate
IB Investigator's Brochure
IC Inhibitory  Concentration
ICF Informed Consent Form
ICH International Conference on Harmonization
IEC Internal Ethics Committee
IgM Immunoglobulin M
IMP Investigational Medicinal Product
INR International Normalized Ratio
IRB Internal Review Board
IUD Intrauterine Device
IUS Intrauterine Hormone -Releasing S ystem
kg Kilogram
KO Knockout
L Liter
LAM Lactational Amenorrhea Method
lb pound
LBF Liver Blood Flow
LH Luteinizing Hormone
m2Square Meter
MABEL Minimum Antic ipated Biological Effect Level
MCH Mean Corpuscular Hemoglobin
MCHC Mean Corpuscular Hemoglobin Concentration
MCV Mean Corpuscular Volume
mg milligram
min minute
mL Milliliter
MRSD Maximum Recommended Starting Dose
MSDS Material Safet y Data Sheet
NCS Not Clinically  Significant
2018N361438_05 CONFIDENTIA L
[ADDRESS_274164]-Natal Day
PO Per Oral
QT QT Interval
QTc Corrected QT Interval
QTcF QT interval corrected according to Fridericia's formula
RAP Reporting and Anal ysis Plan
RBC Red Blood Cells
RCmax Ratio of Cmax
RD Repeat Dose
RNA Ribonucleic Acid
Rss Steady -state Ratio
SAE Serious Adverse Event
SGOT Serum Glutamic -oxaloacetic Transaminase
SGPT Serum Glutamic -Pyruvic Transaminase
SD Single Dose
SOA Schedule of Activities
SOPs Standard Operating Procedures
SRM Study  Reference Manual
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
t1/[ADDRESS_274165] Upper Limit of Normal
WBC White Blood Cell
WT Wildty pe
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_227571]
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE].8. Appendix 8 : Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of Contents (TOC) .
Amendment 1: 31 -AUG -2018
Overall R ationale for the Amendment:   Updates to the PK exposure limits for Parts A 
and B, stoppi[INVESTIGATOR_3418], and safet y review language have been modified based on FDA 
recommendations. Day  -[ADDRESS_274166] the intent of 
collecting but not analy zing Holter Monitoring data in this study .
Section # and Name [CONTACT_23688]
1.3 Schedule of Activities 
(SoARemoval of Day -2 from Part 
C SoAParticipants will not be undergoing 
PD assessments in Part C and 
therefore Day -2 admission is not 
required
2.3 Benefit/Risk 
AssessmentAddition of clarification of 
minimum number and type of 
participants data for dose 
escalation reviewA mini mum of [ADDRESS_274167] 
been increased for Part A and 
decreased for Part B based on 
interpretation and clinical 
management of preclinical findings 
and pharmacokinetic modelling.
2018N361438_05 CONFIDENTIA L
209275
117Section # and Name [CONTACT_23688]
6.[ADDRESS_274168] 
been increased for Part A and 
decreased for Part B based on 
interpretation and clinical 
management of preclinical findings 
and pharmacokinetic modelling.
7.1.3 Individual Stoppi[INVESTIGATOR_227526], AEs, 
and automatic withdrawal from the 
study needed to be more discretely 
defined.
7.1.4 Dose 
Adjustment/Discontinuation 
Pharmacokinet ic CriteriaPK stoppi[INVESTIGATOR_227527] A and 
decreased for Part B based on 
interpretation and clinical 
management of preclinical findings 
and pharmacokinetic mod elling.
[IP_ADDRESS] Safety Study 
Stoppi[INVESTIGATOR_227528], AEs 
criteria for stoppi[INVESTIGATOR_227529].
[IP_ADDRESS] PK Study Stoppi[INVESTIGATOR_227530] y stoppi[INVESTIGATOR_227531] A and 
decreased for Part B based on 
interpretation and clinical 
management of preclinical findings 
and pharmacokinetic modelling.
8.2.[ADDRESS_274169] not been 
summarized
Corrections/clarifications
Amendment 2: 13 -MAR -2019
Overall Rationale for the Amendment: The safety  study  stoppi[INVESTIGATOR_227532] t the intention for the two or more AEs of moderate or severe 
intensity  to be of similar kind. I n addition, we have aligned the protocol to a previous 
2018N361438_05 CONFIDENTIA L
209275
118Note To File (NTF) updating the Schedule of Activities (SoAs), study  design, s tatistical 
analysesand obj ectives and endpoints based on emerging PK data gathered during this 
study .
Section # and Name [CONTACT_23688]
1.[ADDRESS_274170] previously been 
captured in a NTF
7.1Discontinuatio n of 
Study Intervention and 
Participant 
Discontinuation/WithdrawalUpdate to language to 
specify occurrence of similar 
AEsSafety study stoppi[INVESTIGATOR_227533] o or more 
participants.
9.[ADDRESS_274171] previously been 
captured in a NTF
2018N361438_05 CONFIDENTIA L
209275
[ZIP_CODE]. REFERENCES
Abe H, et al. Molecular cloning, chromosome mappi[INVESTIGATOR_227534]2 gene, a putative member of the leukocy te chemoattractant receptor family . Gene 
1999; 227:71 -77.
Boie Y, Sawy er N, Slipetz DM, Metters KM, and Abramovitz M. Molecular cloning and 
characterization of the human prostanoid DP receptor. J Biol Chem 1995; 270:[ZIP_CODE] -
[ZIP_CODE].
Cohen DB, Kawamura S, Ehteshami JR, Rodeo SA. Indomethacin and Celecoxib impair 
rotator cuff tendon -to-bone healing. Amer J Sports Med 2006; 34: 362 -369.
Connizzo, BK et al. The detrimental effects of s ystemic ibuprofen delivery  on tendon 
healing are time dependent. Clin Orthop Relat Res 2014; 472:2433 -2439.
Figueiredo -Pereira ME, Rockwe ll P, Schmidt -Glenewinkel T, Serrano P.  
Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin -
proteasome pathway  and mitochondria to neurodegeneration.  Frontiers in Molecular 
Neuroscience, 2015(7); article 104.
GlaxoSmithKline Docu ment Number 2018N359817_00. I nvestigator’s Brochure for 
[COMPANY_004]3439171A, June 2018.
Hirata T and Narumi ya S. Prostanoid Receptors. Chem Rev 2011. 111; [ADDRESS_274172] in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779 -1784.
Korotkova M, Lundberg IE. The skeletal muscle arachidonic acid cascade in health and 
inflammatory  disease. Nat Rev Rheumatol 2014; 10: [ADDRESS_274173] cells with anti -IgE. J Immun 1982; 
129:1627 -1631.
Mohri I  et al. Inhibition of prostaglandin D s ynthase suppresses muscular necrosis. Amer 
J Pathol 2009; 174: [ADDRESS_274174] s of 
prostanoid biosy nthesis. J Chem Rev 2011; 11: 5821 -5865.
Urade Y and Hay aishi O. Prostaglandin D s ynthase struc ture and function. Vitamins and 
Hormones 2000; 58,89 -120.